Potential of Olfactory Ensheathing Cells from Different Sources for Spinal Cord Repair Anne Mayeur1 ,2 , Ce ' lia Duclos1 , Axel Honore ' 1 , Maxime Gauberti3 , Laurent Drouot4 , Jean-Claude do Rego5 , Nicolas Bon-Mardion1 ,2 , Laetitia Jean4 , Eric Ve ' rin1 , Evelyne Emery3 , Sighild Lemarchant3 , Denis Vivien3 , Olivier Boyer4 ,6 , Jean-Paul Marie1 ,2 , Nicolas Gue ' rout1 * 1 UPRES EA 3830 , Institute for Research and Innovation in Biomedicine , University of Rouen , Rouen , Normandy , France , 2 Otorhinolaryngology , Head and Neck Surgery Department , Rouen University Hospital , Rouen , Normandy , France , 3 Inserm UMR-S 919 , Serine Proteases and Pathophysiology of the Neurovascular Unit , GIP Cyceron , Universite ' de Caen Basse-Normandie , Caen , France , 4 Inserm , U905 , Institute for Biomedical Research and Innovation , University of Rouen , Rouen , Normandy , France , 5 Platform of Behavioural Analysis -LRB- SCAC -RRB- , Institute for Research and Innovation in Biomedicine , Rouen University , France , National Center of Scientific Research -LRB- CNRS -RRB- - DR19 , France , 6 Rouen University Hospital , Department of Immunology , Rouen , Normandy , France Abstract Spinal cord injury -LRB- SCI -RRB- induces a permanent disability in patients .	1
Potential	1
Olfactory Ensheathing Cells from Different Sources for Spinal Cord Repair Anne Mayeur1 ,2	14
Olfactory Ensheathing Cells	14
Different Sources for Spinal Cord Repair Anne Mayeur1 ,2	47
Different Sources	47
Spinal Cord Repair Anne Mayeur1 ,2	69
Ce ' lia Duclos1	105
Ce ' lia	105
Duclos1	113
Axel Honore ' 1	122
Axel Honore '	122
1	135
Maxime Gauberti3	138
Laurent Drouot4	156
Jean-Claude	173
Rego5 , Nicolas Bon-Mardion1 ,2 , Laetitia Jean4 , Eric Ve ' rin1 , Evelyne Emery3 , Sighild Lemarchant3 , Denis Vivien3 , Olivier Boyer4 ,6 , Jean-Paul Marie1 ,2 , Nicolas Gue ' rout1	188
Rego5	188
Nicolas Bon-Mardion1 ,2	195
Laetitia Jean4	219
Eric Ve ' rin1	235
Eric Ve '	235
Evelyne Emery3	250
Sighild Lemarchant3	266
Denis Vivien3	287
Olivier Boyer4 ,6	302
Jean-Paul Marie1 ,2	320
Nicolas Gue ' rout1	340
Nicolas Gue '	340
1 UPRES EA	359
1	359
UPRES EA	361
3830	370
Institute for Research and Innovation in Biomedicine	376
Institute	376
Research and Innovation	390
Biomedicine	417
University of Rouen , Rouen , Normandy , France , 2 Otorhinolaryngology , Head and Neck Surgery Department	430
University	430
Rouen , Rouen , Normandy , France , 2 Otorhinolaryngology , Head and Neck Surgery Department	444
Rouen , Rouen , Normandy , France	444
2 Otorhinolaryngology , Head	476
Neck Surgery Department	508
Rouen University Hospital	533
Rouen	560
Normandy	567
France	577
3 Inserm UMR-S 919	585
3 Inserm UMR-S	585
919	600
Serine Proteases and Pathophysiology of the Neurovascular Unit	605
Serine Proteases and Pathophysiology	605
the Neurovascular Unit	645
GIP Cyceron	669
Universite ' de Caen Basse-Normandie	682
Universite '	682
de Caen Basse-Normandie	694
Caen Basse-Normandie	697
Caen	719
France	725
4 Inserm	733
U905	743
Institute for Biomedical Research and Innovation	749
Institute	749
Biomedical Research and Innovation	763
University of Rouen	799
University	799
Rouen	813
Rouen	820
Normandy	827
France	837
5 Platform of Behavioural Analysis -LRB- SCAC -RRB-	845
5 Platform	845
Behavioural Analysis -LRB- SCAC -RRB-	859
Behavioural Analysis	859
SCAC	881
Institute for Research and Innovation in Biomedicine	888
Institute	888
Research and Innovation	902
Biomedicine	929
Rouen University	942
France	960
National Center of Scientific Research -LRB- CNRS -RRB-	968
National Center	968
Scientific Research -LRB- CNRS -RRB-	987
Scientific Research	987
CNRS	1008
DR19 , France	1016
DR19	1016
France	1022
6 Rouen University Hospital	1030
Department of Immunology , Rouen , Normandy , France Abstract Spinal cord injury -LRB- SCI -RRB- induces a permanent disability in patients	1059
Department	1059
Immunology , Rouen , Normandy , France Abstract Spinal cord injury -LRB- SCI -RRB- induces a permanent disability in patients	1073
Immunology , Rouen , Normandy , France Abstract	1073
Spinal cord injury -LRB- SCI -RRB-	1119
Spinal cord injury	1119
SCI	1139
a permanent disability in patients	1152
a permanent disability	1152
patients	1178
this day	1191
no curative treatment	1200
lost functions	1249
extensive experimental studies	1276
recovery	1337
SCI	1352
One of the most promising therapies	1357
One	1357
the most promising therapies	1364
the use of olfactory ensheathing cells -LRB- OECs -RRB-	1405
the use	1405
olfactory ensheathing cells -LRB- OECs -RRB-	1416
olfactory ensheathing cells	1416
OECs	1445
OECs	1452
either the olfactory bulbs -LRB- OB-OECs -RRB-	1478
either the olfactory bulbs	1478
OB-OECs	1506
olfactory mucosa -LRB- OM-OECs -RRB- , involving a less invasive approach for autotransplantation	1523
olfactory mucosa	1523
OM-OECs	1541
a less invasive approach for autotransplantation	1561
a less invasive approach	1561
autotransplantation	1590
the vast majority of experimental transplantations	1619
the vast majority	1619
experimental transplantations	1640
OB-OECs	1692
the OM	1709
a more accessible source of OECs	1727
a more accessible source	1727
OECs	1755
the ability of OM-OECs in comparison to OB-OECs to induce spinal cord recovery in the same lesion paradigm	1774
the ability	1774
OM-OECs in comparison to OB-OECs to induce spinal cord recovery in the same lesion paradigm	1789
OM-OECs	1789
comparison to OB-OECs to induce spinal cord recovery in the same lesion paradigm	1800
comparison	1800
OB-OECs to induce spinal cord recovery in the same lesion paradigm	1814
spinal cord recovery in the same lesion paradigm	1832
spinal cord recovery	1832
the same lesion paradigm	1856
We	1907
present data	1915
a multiparametric approach , based on electrophysiological , behavioral , histological and magnetic resonance imaging experiments on the repair potential of OB-OECs and OM-OECs from either primary or purified cultures after a severe model of SCI	1934
a multiparametric approach	1934
electrophysiological , behavioral , histological and magnetic resonance imaging experiments	1971
the repair potential of OB-OECs and OM-OECs	2064
the repair potential	2064
OB-OECs and OM-OECs	2088
primary	2120
cultures	2140
a severe model of SCI	2155
a severe model	2155
SCI	2173
Our data	2178
transplantation of OECs obtained from OB or OM	2204
transplantation	2204
OECs obtained from OB or OM	2223
OECs	2223
OB or OM	2242
electrophysiological and functional recovery	2259
astrocyte reactivity and glial scar formation	2313
astrocyte reactivity	2313
glial scar formation	2338
axonal regrowth	2372
We	2389
the purification step	2407
OM-OECs	2446
OB-OECs	2477
our study	2498
transplantation of OECs from OM	2532
transplantation	2532
OECs from OM	2551
OECs	2551
OM	2561
the best benefit/risk ratio	2575
the safety of access of OM and the results induced by transplantations of OM-OECs	2616
the safety of access of OM	2616
the safety	2616
access of OM	2630
access	2630
OM	2640
the results induced by transplantations of OM-OECs	2647
the results	2647
transplantations of OM-OECs	2670
transplantations	2670
OM-OECs	2690
purified OM-OECs in addition to induce recovery	2707
purified OM-OECs	2707
addition to induce recovery	2727
recovery	2746
60 days	2787
the spinal cord	2800
our results	2828
strong support	2848
these cells as a viable therapy for SCI	2867
these cells	2867
a viable therapy for SCI	2882
a viable therapy	2882
SCI	2903
Introduction Spinal cord injury -LRB- SCI -RRB-	2909
Introduction Spinal cord injury	2909
Introduction	2909
Spinal cord injury	2922
SCI	2942
a devastating disease leading to a loss of neural conduction	2950
a devastating disease	2950
a loss of neural conduction	2983
a loss	2983
neural conduction	2993
Sensory and motor pathways	3012
paraplegia or tetraplegia	3068
patients	3098
SCI several mechanisms	3114
place such as astrocyte reactivity , formation of the glial scar	3142
place	3142
astrocyte reactivity , formation of the glial scar	3156
astrocyte reactivity	3156
formation of the glial scar	3178
formation	3178
the glial scar	3191
invasion of inflammatory cells resulting in a lack of axonal regrowth	3207
invasion	3207
inflammatory cells resulting in a lack of axonal regrowth	3219
inflammatory cells	3219
a lack of axonal regrowth	3251
a lack	3251
axonal regrowth	3261
1,2 -RSB-	3278
this day	3287
no curative treatment	3296
clinical use	3335
extensive experimental studies	3359
axonal regrowth	3422
functional recovery	3453
SCI using various therapies -LSB- 3,4 -RSB-	3479
SCI	3479
various therapies -LSB- 3,4 -RSB-	3489
various therapies	3489
3,4 -RSB-	3508
Many of these approaches	3514
Many	3514
these approaches	3522
cellular transplantation , such as Schwann cells -LRB- SC -RRB- , neural stem cells ,	3549
cellular transplantation	3549
Schwann cells -LRB- SC -RRB- , neural stem cells	3583
Schwann cells -LRB- SC -RRB-	3583
Schwann cells	3583
SC	3598
neural stem cells	3603
pluripotent stem cells or olfactory ensheathing cells	3630
OECs , `` OECs ''	3685
all the olfactory ensheathing cells	3716
contrasting results -LSB- 5	3758
contrasting results	3758
5	3779
12	3781
OECs	3786
considerable interest for the past decade due to the fact	3803
considerable interest	3803
the past decade due to the fact	3829
the past decade	3829
the fact	3852
OECs	3866
a great potential	3882
both functional and anatomical recoveries	3911
SCI	3959
13 -RSB-	3964
OECs	3969
neural crest cells which participate to neurogenesis occurring in the primary olfactory system throughout life in mammals -LSB- 14 -RSB-	3978
neural crest cells	3978
neurogenesis occurring in the primary olfactory system throughout life in mammals -LSB- 14 -RSB-	4018
neurogenesis	4018
the primary olfactory system throughout life	4044
the primary olfactory system	4044
life	4084
mammals -LSB- 14 -RSB-	4092
mammals	4092
14 -RSB-	4101
transplantation in lesioned spinal cord	4116
transplantation	4116
lesioned spinal cord	4135
OECs	4157
axonal regrowth	4184
astrocyte reactivity , increase angiogenesis	4210
astrocyte reactivity	4210
increase angiogenesis	4232
glial scar leading	4267
functional recovery in various models of SCI in rodents -LSB- 15 -- 19 -RSB-	4289
functional recovery	4289
various models of SCI in rodents -LSB- 15 -- 19 -RSB-	4312
various models	4312
SCI in rodents -LSB- 15 -- 19 -RSB-	4330
SCI	4330
rodents -LSB- 15 -- 19 -RSB-	4337
rodents	4337
15 -- 19	4346
OECs	4364
several subpopulations	4388
the role of each of them following transplantation in injured spinal cord	4415
the role	4415
each of them following transplantation in injured spinal cord	4427
each	4427
them	4435
transplantation in injured spinal cord	4450
transplantation	4450
injured spinal cord	4469
20,21 -RSB-	4512
OECs	4534
two different regions : olfactory mucosa -LRB- OM -RRB- and olfactory bulbs -LRB- OB -RRB-	4560
two different regions	4560
olfactory mucosa -LRB- OM -RRB- and olfactory bulbs -LRB- OB -RRB-	4583
olfactory mucosa -LRB- OM -RRB-	4583
olfactory mucosa	4583
OM	4601
olfactory bulbs -LRB- OB -RRB-	4609
olfactory bulbs	4609
OB	4626
it	4634
OECs obtained from OM -LRB- OM-OECs -RRB- and OB -LRB- OB-OECs -RRB-	4650
OECs	4650
OM -LRB- OM-OECs -RRB- and OB -LRB- OB-OECs -RRB-	4669
OM	4669
OM-OECs	4673
OB	4686
OB-OECs	4690
the same properties and effects after transplantation in vivo -LSB- 22,23 -RSB-	4708
the same properties and effects	4708
transplantation in vivo -LSB- 22,23 -RSB-	4746
transplantation	4746
22,23 -RSB-	4771
culture conditions , in particular the presence of microenvironment ,	4789
culture conditions	4789
particular the presence of microenvironment	4812
particular the presence	4812
microenvironment	4839
OECs behaviors in vitro and in vivo	4879
OECs behaviors	4879
vivo	4910
21,24 -RSB-	4916
OM-OECs	4924
primary olfactory neurons and fibroblasts	4960
OB	5011
OECs	5015
contact with fibroblasts and astrocytes both in vitro and in vivo -LSB- 25 -- 28	5027
contact with fibroblasts and astrocytes	5027
contact	5027
fibroblasts and astrocytes	5040
in vitro and in vivo -LSB- 25 -- 28	5072
in vitro and in vivo -LSB-	5072
vivo	5088
25 -- 28	5094
a clinical purpose	5106
these two aspects	5125
some relevant consequences	5148
clinical use	5188
OECs	5202
autotransplantation	5229
a simple biopsy of OM	5259
a simple biopsy	5259
OM	5278
Rubio et al.	5317
Rubio	5317
et al.	5323
an unilateral bulbectomy	5337
OB -LSB- 29 -RSB-	5367
OB	5367
29 -RSB-	5371
OECs	5389
primary cultures	5424
additional purification steps	5450
it	5484
time in culture	5510
time	5510
culture	5518
neurogenic properties of OECs -LSB- 30,31 -RSB-	5536
neurogenic properties	5536
OECs -LSB- 30,31 -RSB-	5561
OECs	5561
30,31 -RSB-	5567
we	5580
the potential of OECs obtained and purified from the two sources in a severe model of SCI by a multiparametric approach	5606
the potential	5606
OECs obtained and purified from the two sources in a severe model of SCI by a multiparametric approach	5623
OECs	5623
the two sources	5655
a severe model of SCI	5674
a severe model	5674
SCI	5692
a multiparametric approach	5699
We	5727
transplantation of OECs	5747
transplantation	5747
OECs	5766
electrophysiological and functional recovery	5779
astrocyte reactivity and glial scar formation	5833
astrocyte reactivity	5833
glial scar formation	5858
axonal regrowth	5892
our model	5922
transplantation of OECs from OM	5933
transplantation	5933
OECs from OM	5952
OECs	5952
OM	5962
the best benefit/risk source	5976
support for these cells	6016
support	6016
these cells	6028
a new therapy for SCI	6043
a new therapy	6043
SCI	6061
human	6068
Materials and Methods General Overview An overview of the paradigms used in this study	6076
Materials	6076
Methods General Overview An overview of the paradigms used in this study	6090
Methods General Overview An overview	6090
Methods	6090
General Overview	6098
An overview	6115
the paradigms used in this study	6130
the paradigms	6130
this study	6152
Figure 1	6179
cellular transplantations	6198
complete transection of the spinal cord	6245
complete transection	6245
the spinal cord	6269
two sources -LRB- OB and OM -RRB-	6290
two sources	6290
OB and OM	6303
OB	6303
OM	6310
two different ways -LRB- primary and purified -RRB-	6330
two different ways	6330
primary and purified	6350
OB -LRB- Primary OB -RRB- and OM -LRB- Primary OM -RRB-	6377
OB	6377
Primary OB	6381
OM	6397
Primary OM	6401
primary cultures	6414
5 days in vitro -LRB- DIV -RRB-	6455
5 days	6455
vitro	6465
DIV	6472
OB -LRB- Purified OB -RRB-	6482
OB	6482
OB	6495
purified cultures	6500
10 DIV	6542
OM -LRB- Purified OM -RRB-	6554
OM	6554
OM	6567
purified cultures	6572
14 DIV	6614
All different cell types	6622
spinal cord transection	6683
All groups of animals	6708
All groups	6708
animals	6722
15 , 30 and 60 days after surgery	6744
15	6744
30 and 60 days after surgery	6748
30 and 60 days	6748
surgery	6769
electrophysiological and locomotor activities	6781
Histological analyses	6828
60 days	6873
transplantation	6887
all the groups	6907
additional animals treated with Md , Primary OB and Purified OM , which showed higher potential to promote recovery ,	6929
additional animals	6929
Md , Primary OB	6961
Md	6961
Primary OB	6965
OM	6989
higher potential to promote recovery	7006
higher potential	7006
recovery	7034
MRI analyses	7058
7 days	7071
transplantation	7084
OM purified cells , which constituted the most relevant group for clinical use ,	7110
OM	7110
cells	7122
the most relevant group for clinical use	7147
the most relevant group	7147
clinical use	7175
GFP	7207
them	7224
30 and 60 days after transplantation	7229
30 and 60 days	7229
transplantation	7250
Animals Experiments	7267
acceptance	7308
the local Ethics Committee for Animal Experiments in Normandy	7322
the local Ethics Committee	7322
Animal Experiments in Normandy	7353
Animal Experiments	7353
Normandy	7375
N/02 - 11-10/22	7385
N/02	7385
11-10/22	7391
11-13 in accordance	7400
11-13	7400
accordance	7409
the French law	7425
the protection of animals	7443
the protection	7443
animals	7461
this study , 95 8-weeks old and 30 3 -- 4 weeks old male	7474
this study	7474
95 8-weeks old	7486
30 3 -- 4 weeks old male	7505
30 3	7505
4 weeks old male	7510
4 weeks	7510
inbred Fischer rats	7527
Charles River	7558
L'Arbresle , France	7573
Individual rats	7594
implantation of glass tag -LRB- Biolog-id , Bernay , France -RRB-	7629
implantation	7629
glass tag -LRB- Biolog-id , Bernay , France -RRB-	7645
glass tag	7645
Biolog-id	7656
Bernay	7667
France	7675
glass tag numbers	7684
analyses	7736
Cell Culture All cultures	7746
Cell Culture	7746
All cultures	7759
semi-sterile conditions	7795
autoclaved surgery tools	7824
Primary cultures	7850
OB and OM primary cultures	7868
slight modifications -LSB- 25,26 -RSB-	7938
slight modifications	7938
25,26 -RSB-	7960
rats	7977
isofluorane	8008
OB from one rat	8038
OB	8038
one rat	8046
1 ml of Hank 's buffered salt solution -LRB- H.B.S.S , Invitrogen , Carlsbad , CA -RRB-	8095
1 ml	8095
Hank 's	8103
salt solution -LRB- H.B.S.S , Invitrogen , Carlsbad , CA -RRB-	8119
salt solution	8119
H.B.S.S	8134
Invitrogen	8143
Carlsbad , CA	8155
the meninges	8185
H.B.S.S containing 0.1 % trypsin -LRB- Invitrogen -RRB- and OB	8199
H.B.S.S	8199
0.1 % trypsin -LRB- Invitrogen -RRB- and OB	8218
0.1 % trypsin -LRB- Invitrogen -RRB-	8218
0.1 % trypsin	8218
Invitrogen	8232
OB	8248
45 min at 37 °C	8270
45 min	8270
37 °C	8280
Trypsinization	8286
Dulbecco 's	8323
Eagle 's	8343
Ham 's F12 medium -LRB- D.M.E.M / F12 , Invitrogen -RRB- , supplemented with 10 % Fetal Bovine Serum -LRB- F.B.S , Invitrogen -RRB- and 1 % penicillin/streptomycin -LRB- Invitrogen -RRB- -LRB- DF-10S -RRB-	8351
Ham 's F12 medium -LRB- D.M.E.M / F12 , Invitrogen -RRB- , supplemented with 10 % Fetal Bovine Serum -LRB- F.B.S , Invitrogen -RRB-	8351
Ham 's F12 medium -LRB- D.M.E.M / F12 , Invitrogen -RRB-	8351
Ham 's F12 medium	8351
Ham 's	8351
D.M.E.M	8369
F12 , Invitrogen	8377
F12	8377
Invitrogen	8382
10 % Fetal Bovine Serum	8413
F.B.S	8437
Invitrogen	8444
1 % penicillin/streptomycin -LRB- Invitrogen -RRB- -LRB- DF-10S -RRB-	8460
1 % penicillin/streptomycin -LRB- Invitrogen -RRB-	8460
1 % penicillin/streptomycin	8460
Invitrogen	8488
DF-10S	8501
The tissue	8510
1.000 RPM for 3 min	8542
1.000 RPM	8542
3 min	8556
DF-10S	8578
Tissue	8610
3 ml DF-10S using a micropipette	8640
3 ml DF-10S	8640
a micropipette	8658
a homogenous cell suspension	8680
undigested tissue blocks	8738
pipetting	8779
cells	8796
1.5 -- 3.106 cells per flask	8815
1.5	8815
3.106 cells per flask	8819
3.106 cells	8819
flask	8835
DF-10S in 25 cm2 flasks -LRB- Starlab , Bagneux , France -RRB-	8845
DF-10S	8845
25 cm2 flasks -LRB- Starlab , Bagneux , France -RRB-	8855
25 cm2 flasks	8855
Starlab	8870
Bagneux	8879
France	8888
poly-L-Lysine -LRB- 50 µg / ml , Invitrogen -RRB-	8913
poly-L-Lysine	8913
50 µg	8928
ml , Invitrogen	8935
ml	8935
Invitrogen	8939
The flasks	8952
37 °C , 5 % CO2	8981
37 °C	8981
5 % CO2	8987
The medium	8995
every two days	9018
Five days	9034
OB primary cultures	9059
transplantation	9093
the same rats	9113
the nasal cavity	9128
a spatula	9172
OM	9186
small pieces	9200
Care	9214
cartilage	9246
a short rinse in H.B.S.S	9263
a short rinse	9263
H.B.S.S	9280
samples from 1 rat	9289
samples	9289
1 rat	9302
1 ml of collagenase A -LRB- 0.5 % -RRB-	9339
1 ml	9339
collagenase A -LRB- 0.5 % -RRB-	9347
collagenase A	9347
0.5 %	9362
45 min at 37 °C -LRB- Roche Diagnostics , Penzbeg , Germany -RRB-	9372
45 min	9372
37 °C -LRB- Roche Diagnostics , Penzbeg , Germany -RRB-	9382
37 °C	9382
Roche Diagnostics	9388
Penzbeg	9407
Germany	9416
The OM	9425
the rat by its posterior position on the nasal septum and by the yellowish appearance of the epithelial surface	9456
the rat	9456
its posterior position on the nasal septum	9467
its posterior position	9467
the nasal septum	9493
the yellowish appearance of the epithelial surface	9517
the yellowish appearance	9517
the epithelial surface	9545
Care	9569
the anterior edge of the OM which could have been contaminated with respiratory epithelium	9593
the anterior edge	9593
the OM which could have been contaminated with respiratory epithelium	9614
the OM	9614
respiratory epithelium	9661
Respiratory mucosa	9685
the dorso-anterior region of the septum	9721
the dorso-anterior region	9721
the septum	9750
samples	9768
the same protocol that for OB cultures -LSB- 25 -RSB-	9797
the same protocol	9797
OB cultures	9824
25 -RSB-	9837
Five days	9842
OM primary cultures	9867
transplantation	9901
Olfactory ensheathing cells purification .	9918
Olfactory ensheathing cells	9918
purification	9946
OECs purification from OB	9960
OECs purification	9960
OB	9983
method described by Nash based on the differing rates of attachment of the various harvested cell types -LSB- 32 -RSB-	10010
method	10010
Nash	10030
the differing rates of attachment of the various harvested cell types -LSB- 32 -RSB-	10044
the differing rates	10044
attachment of the various harvested cell types -LSB- 32 -RSB-	10067
attachment	10067
the various harvested cell types -LSB- 32 -RSB-	10081
the various	10081
cell types -LSB- 32 -RSB-	10103
cell types	10103
32 -RSB-	10115
the method of differential adhesion	10129
the method	10129
differential adhesion	10143
a very low adhesion rate of OEC	10177
a very low adhesion rate	10177
OEC	10205
the surface of uncoated culture flasks -LSB- 32,33 -RSB-	10212
the surface	10212
uncoated culture flasks -LSB- 32,33 -RSB-	10227
uncoated culture flasks	10227
32,33 -RSB-	10252
The cell suspension obtained from OB	10260
The cell suspension	10260
OB	10294
DF-10S	10316
uncoated flask	10334
37 °C with 5 % CO2	10365
37 °C	10365
5 % CO2	10375
18 h	10389
the supernatant	10395
other uncoated flasks	10440
additional 36 h	10480
The supernatants from these flasks	10497
The supernatants	10497
these flasks	10519
25 cm2	10561
poly-L-lysine-coated culture flasks	10568
DF-10S	10609
Ten days	10617
OB purified cultures	10641
OB	10641
cultures	10653
transplantation	10676
OECs purification from OM	10693
OECs purification	10693
OM	10716
the method described by Bianco and modified by Gueye et al. -LSB- 34,35 -RSB-	10742
the method	10742
Bianco	10766
Gueye et al. -LSB-	10789
34,35 -RSB-	10803
one week in primary culture	10826
one week	10826
primary culture	10838
cells	10855
trypsinisation	10875
serum-free culture medium supplemented with 25 ng/mL of transforming growth factor a -LRB- Sigma Aldrich , St Louis , MO -RRB- onto pre-coated flasks -LRB- poly-L-Lysine 50 µg/ml -RRB-	10906
serum-free culture medium	10906
25 ng/mL of transforming growth factor a -LRB- Sigma Aldrich , St Louis , MO -RRB- onto pre-coated flasks -LRB- poly-L-Lysine 50 µg/ml -RRB-	10950
25 ng/mL	10950
growth factor	10975
a -LRB- Sigma Aldrich , St Louis , MO -RRB-	10989
Sigma Aldrich	10992
St Louis	11007
MO	11017
pre-coated flasks -LRB- poly-L-Lysine 50 µg/ml -RRB-	11026
pre-coated flasks	11026
poly-L-Lysine 50 µg/ml	11045
poly-L-Lysine	11045
50 µg/ml	11059
The second passage	11070
1 week	11103
Fourteen days	11117
OM purified cultures	11146
OM	11146
cultures	11158
transplantation	11181
Preparation of the cells for grafting .	11198
Preparation	11198
the cells for grafting	11213
the cells	11213
grafting	11227
transplantation	11244
cultures	11261
them	11297
the dishes	11307
the cells	11323
a hemocytometer	11352
Cultures cells	11369
DF-10S	11404
a final concentration of 100,000 cells/µl	11443
a final concentration	11443
100,000 cells/µl	11468
Samples of the different cultures	11486
Samples	11486
the different cultures	11497
characterization	11538
Flow-cytometry analysis of OECs .	11575
Flow-cytometry analysis	11575
OECs	11602
cellular preparations	11633
flow-cytometry analysis	11656
The cells	11695
PBS	11722
trypsin/EDTA in conjunction	11743
trypsin/EDTA	11743
conjunction	11759
the use of a cell scraper	11776
the use	11776
a cell scraper	11787
adherent cells	11812
cells	11834
PBS/EDTA	11857
15 min at 4uC	11892
15 min	11892
4uC	11902
the the anti-p75LNGFr -LRB- 1:100 -RRB- -LRB- Chemicon , Billerica , MA . -RRB-	11912
the the anti-p75LNGFr -LRB- 1:100 -RRB-	11912
the the anti-p75LNGFr	11912
1:100	11935
Chemicon	11943
Billerica	11953
MA .	11964
.	11968
the end of the incubation	11973
the end	11973
the incubation	11984
2 ml of PBS/EDTA	12000
2 ml	12000
PBS/EDTA	12008
the cells	12031
300 g for 5 min	12059
300 g	12059
5 min	12069
Cells	12077
the secondary antibodies conjugated with phycoerythrin -LRB- 1:200 -RRB- for p75 -LRB- BD Biosciences , San Jose , CA -RRB-	12103
the secondary antibodies	12103
phycoerythrin -LRB- 1:200 -RRB- for p75 -LRB- BD Biosciences , San Jose , CA -RRB-	12144
phycoerythrin -LRB- 1:200 -RRB-	12144
phycoerythrin	12144
1:200	12159
p75 -LRB- BD Biosciences , San Jose , CA -RRB-	12170
p75	12170
BD Biosciences	12175
San Jose	12191
CA	12201
the end of the incubation	12209
the end	12209
the incubation	12220
2 ml of PBS/EDTA	12236
2 ml	12236
PBS/EDTA	12244
the cells	12267
300 g for 5 min	12295
300 g	12295
5 min	12305
cells	12319
500 µl of PBS/EDTA	12345
500 µl	12345
PBS/EDTA	12355
The total number of 10,000 events	12365
The total number	12365
10,000 events	12385
a FACSCalibur flowcytometer -LRB- BD Biosciences -RRB-	12415
a FACSCalibur flowcytometer	12415
BD Biosciences	12444
the staining procedure	12475
Data	12499
the FACSdiva program -LRB- BD Biosciences -RRB-	12525
the FACSdiva program	12525
BD Biosciences	12547
Proportion of p75 positive cells in the various samples	12564
Proportion	12564
p75 positive cells in the various samples	12578
p75 positive cells	12578
the various samples	12600
the fluorescence intensity dot plot	12648
the total amount of non-labeled cells	12696
the total amount	12696
non-labeled cells	12716
Flow cytometry analysis	12735
that OB primary cultures contained approximately 70 % of p75 positive cells -LRB- Figure 2A -RRB- and OB purified cultures	12782
that OB	12782
primary cultures	12790
approximately 70 % of p75 positive cells -LRB- Figure 2A -RRB- and OB purified cultures	12817
approximately 70 % of p75 positive cells -LRB- Figure 2A -RRB-	12817
approximately 70 %	12817
p75 positive cells -LRB- Figure 2A -RRB-	12838
p75 positive cells	12838
Figure 2A	12858
OB purified cultures	12873
OB	12873
cultures	12885
approximately 97 % of p75	12904
approximately 97 %	12904
p75	12925
positive cells -LRB- Figure 2B -RRB- , whereas in the same time OM cultures contained about 15 % of p75 positive cells -LRB- Figure 2C -RRB- and OM purified cultures contained approximately 98 % of p75 positive cells -LRB- Figure 2D -RRB-	12929
positive cells	12929
Figure 2B	12945
the same time	12968
OM cultures	12982
about 15 % of p75 positive cells -LRB- Figure 2C -RRB- and OM purified cultures contained approximately 98 % of p75 positive cells -LRB- Figure 2D -RRB-	13004
about 15 % of p75 positive cells -LRB- Figure 2C -RRB-	13004
about 15 %	13004
p75 positive cells -LRB- Figure 2C -RRB-	13017
p75 positive cells	13017
Figure 2C	13037
OM purified cultures contained approximately 98 % of p75 positive cells -LRB- Figure 2D -RRB-	13052
OM	13052
cultures	13064
approximately 98 % of p75 positive cells -LRB- Figure 2D -RRB-	13083
approximately 98 %	13083
p75 positive cells -LRB- Figure 2D -RRB-	13104
p75 positive cells	13104
Figure 2D	13124
GFP labeling of transplanted cells .	13136
GFP labeling	13136
transplanted cells	13152
This evaluation	13172
6 other rats	13205
OM group	13231
3 rats	13241
each time point -LRB- 30 and 60 days -RRB-	13261
each time point	13261
30 and 60 days	13278
30	13278
60 days	13285
five days before transplantation , OM-OECs purified cultures were infected with a lentiviral vector harboring	13304
five days	13304
transplantation , OM-OECs purified cultures were infected with a lentiviral vector harboring	13321
transplantation	13321
OM-OECs purified cultures were infected with a lentiviral vector harboring	13338
OM-OECs	13338
cultures	13355
a lentiviral vector harboring	13383
GFP -LRB- multiplicity of infection : 20 , time of exposure overnight -RRB-	13422
GFP	13422
multiplicity of infection : 20 , time of exposure overnight	13427
multiplicity of infection : 20 , time	13427
multiplicity of infection	13427
multiplicity	13427
infection	13443
20 , time	13454
20	13454
time	13458
exposure overnight	13466
infection	13502
80 %	13516
flow cytometry	13534
materials and methods	13578
several washing steps	13609
GFP positive cells	13632
Experimental Spinal Cord Lesion and Cell Transplantation Procedure	13685
experimental groups	13756
adult Fischer inbred rats -LRB- 225 -- 250 g -RRB-	13777
adult Fischer inbred rats	13777
adult Fischer	13777
225 -- 250 g	13804
225	13804
250 g	13808
All the rats	13826
intraperitoneal injection of ketamine hydrochloride -LRB- 12.5 mg/kg -RRB- and chlorpromazine hydrochloride -LRB- 0.625 mg/kg -RRB-	13860
intraperitoneal injection	13860
ketamine hydrochloride -LRB- 12.5 mg/kg -RRB- and chlorpromazine hydrochloride -LRB- 0.625 mg/kg -RRB-	13889
ketamine hydrochloride	13889
12.5 mg/kg	13913
chlorpromazine hydrochloride	13929
0.625 mg/kg	13959
Five groups -LRB- n = 10 -RRB-	13973
Five groups	13973
n	13986
10	13989
Group 1 : Medium group -LRB- Md -RRB-	14021
Group 1	14021
Medium group -LRB- Md -RRB-	14030
Medium group	14030
Md	14044
Complete spinal cord transection	14049
DF-10S	14100
Group 2 : OB-treated group -LRB- Primary OB -RRB- .	14121
Group 2	14121
OB-treated group -LRB- Primary OB -RRB-	14130
OB-treated group	14130
Primary OB	14148
Complete spinal cord transection	14161
primary olfactory bulb cultures	14212
Group 3 : OM-treated group -LRB- Primary OM -RRB- .	14263
Group 3	14263
OM-treated group -LRB- Primary OM -RRB-	14272
OM-treated group	14272
Primary OM	14290
Complete spinal cord transection	14303
primary olfactory mucosa cultures	14354
Group 4 : OB OECs-treated group -LRB- Purified OB -RRB- .	14407
Group 4	14407
OB OECs-treated group -LRB- Purified OB -RRB-	14416
OB OECs-treated group	14416
OB	14448
Complete spinal cord transection was performed and purified olfactory ensheathing cells from olfactory bulb	14453
Complete spinal cord transection	14453
olfactory ensheathing cells	14513
olfactory bulb	14546
Group 5 : OM OECs-treated group -LRB- Purified OM -RRB- .	14580
Group 5	14580
OM OECs-treated group -LRB- Purified OM -RRB-	14589
OM OECs-treated group	14589
OM	14621
Complete spinal cord transection was performed and purified olfactory ensheathing cells from olfactory mucosa	14626
Complete spinal cord transection	14626
olfactory ensheathing cells	14686
olfactory mucosa	14719
Control animals -LRB- Ctrl -RRB-	14755
Control animals	14755
Ctrl	14772
histological analyses	14797
these no surgery was performed	14824
these	14824
no surgery	14830
all operated groups	14860
all	14860
groups	14873
surgery	14880
the same operator	14905
a midline dorsal incision	14942
a standard bilateral Th10 laminectomy	14969
great care	15026
the spinal cord	15060
The dura	15077
the level of the Th10 dorsal root	15129
the level	15129
the Th10 dorsal root	15142
the spinal cord	15170
a microscalpel	15216
the cord stumps	15232
a needle	15264
the two stumps	15292
completeness of the lesion	15317
completeness	15317
the lesion	15333
spinal cord transection	15363
cells or medium	15388
a 5 µl	15428
Hamilton glass syringe	15435
a 27 gauge needle	15472
a micromanipulator	15506
Md treated animals	15526
injection of DF-10S	15554
injection	15554
DF-10S	15567
transplanted animals	15579
cellular preparations	15609
Medium or cells	15632
the spinal cord on the site of the lesion	15665
the spinal cord	15665
the site of the lesion	15684
the site	15684
the lesion	15696
Injections	15708
spinal sites 1.5 mm laterally from the midline -LRB- 2 sites -RRB- and 2 mm depth : 1 mm rostrally and 1 mm	15737
spinal sites 1.5 mm laterally from the midline -LRB- 2 sites -RRB- and 2 mm depth : 1 mm rostrally	15737
spinal sites	15737
1.5 mm laterally from the midline -LRB- 2 sites -RRB- and 2 mm depth : 1 mm rostrally	15750
1.5 mm	15750
the midline -LRB- 2 sites -RRB- and 2 mm depth : 1 mm	15772
the midline -LRB- 2 sites -RRB-	15772
the midline	15772
2 sites	15785
2 mm depth : 1 mm	15798
2 mm depth	15798
1 mm	15810
1 mm	15829
Each animal	15844
a total of 4 injections -LRB- 4x1 µl -RRB- which contained cellular suspension -LRB- 100,000 cells/µl -RRB- or DF-10S	15865
a total	15865
4 injections -LRB- 4x1 µl -RRB- which contained cellular suspension -LRB- 100,000 cells/µl -RRB- or DF-10S	15876
4 injections	15876
4x1 µl	15890
cellular suspension -LRB- 100,000 cells/µl -RRB- or DF-10S	15914
cellular suspension	15914
100,000 cells/µl	15935
DF-10S	15956
The injection	15964
0.5 µl / min	15991
0.5 µl	15991
min	15999
The delivery needle	16004
the injection site for 2 min	16036
the injection site	16036
2 min	16059
reflux	16074
No immunosuppressant	16082
All the rats	16113
heat lamp	16156
24 hours	16173
surgery	16188
antibiotics for the first two weeks -LRB- Ceftriaxone , 80 mg/Kg -RRB-	16205
antibiotics	16205
the first two weeks -LRB- Ceftriaxone , 80 mg/Kg -RRB-	16221
the first two weeks	16221
Ceftriaxone	16242
80 mg/Kg	16255
the experiments	16283
rats	16300
standard laboratory food and tap water ad libitum	16318
standard laboratory food	16318
tap water ad libitum	16347
an artificial 12 hours light/dark cycle	16374
12 hours	16388
threes	16427
all the experiments	16442
the bladder	16462
every day	16489
manual abdominal pressure	16502
rats	16532
all the precautions taken a high morbidity has been recorded , around 30 % , thereby to obtain 10 rats in every group	16564
all the precautions	16564
a high morbidity	16590
30 %	16633
10 rats in every group	16656
10 rats	16656
every group	16667
15 rats per group	16679
15 rats	16679
group	16691
95 rats	16712
this study	16739
Evaluation Evaluations	16751
15 , 30 and 60 days after surgery for electrophysiological and behavioral analyses and at 60 days	16789
15	16789
30 and 60 days after surgery for electrophysiological and behavioral analyses and at 60 days	16793
30 and 60 days	16793
surgery for electrophysiological and behavioral analyses	16814
surgery	16814
electrophysiological and behavioral analyses	16826
60 days	16878
surgery for histological analysis	16892
surgery	16892
histological analysis	16904
10 rats per group	16929
10 rats	16929
group	16941
GFP	16960
positive OECs	16964
30 and 60 days after surgery	16995
30 and 60 days	16995
surgery	17016
6 other rats for Purified OM treated group	17027
6 other rats	17027
OM treated group	17053
OM	17053
group	17064
Experimental schedule	17071
Figure 1	17109
Electrophysiological studies	17119
Measurement of cord dorsum potentials -LRB- CDP -RRB-	17149
Measurement of cord dorsum potentials	17149
Measurement	17149
cord dorsum potentials	17164
CDP	17188
this	17211
rats	17217
ketamine hydrochloride -LRB- 30 mg/kg -RRB-	17246
ketamine hydrochloride	17246
30 mg/kg	17270
slight sedation	17299
an electrode	17322
the abdomen of the rats for electrical isolation	17366
the abdomen	17366
the rats for electrical isolation	17381
the rats	17381
electrical isolation	17394
CDP	17419
two recording electrodes placed in gastrocnemius muscles separated by 5 mm	17443
two recording electrodes	17443
gastrocnemius muscles separated by 5 mm	17478
gastrocnemius muscles	17478
5 mm	17513
spinal cord	17528
sub-lesional	17563
the record	17588
Stimulations	17600
Th2 level -LRB- above the lesion site -RRB-	17631
Th2 level	17631
the lesion site	17648
a magnetic stimulator -LRB- Magstrim , Rapid 2 ® -RRB-	17671
a magnetic stimulator	17671
Magstrim , Rapid 2 ®	17694
Magstrim , Rapid	17694
Magstrim	17694
Rapid	17704
2 ®	17710
5 stimulations separated by 30 seconds with an intensity of 90 % for supra maximal response	17717
5 stimulations	17717
30 seconds with an intensity of 90 % for supra maximal response	17745
30 seconds	17745
an intensity of 90 % for supra maximal response	17761
an intensity	17761
90 % for supra maximal response	17777
90 %	17777
supra maximal response	17785
amplitude	17815
each animal	17855
Measurement of locomotor activity .	17868
Measurement	17868
locomotor activity	17883
Measurement of locomotor activity	17903
Measurement	17903
locomotor activity	17918
36 -RSB-	17976
Animals	17981
40x40x30 cm compartments	18017
a lighted and quiet room	18046
Locomotor activity	18072
a computerized actimeter -LRB- Versamax , AccuScan Instruments Inc , Ohio , USA -RRB- , which monitored the horizontal displacements and vertical movements , including vertical time and vertical activity	18121
a computerized actimeter -LRB- Versamax , AccuScan Instruments Inc , Ohio , USA -RRB-	18121
a computerized actimeter	18121
Versamax , AccuScan Instruments Inc , Ohio , USA	18147
Versamax	18147
AccuScan Instruments Inc	18157
Ohio	18183
USA	18189
the horizontal displacements and vertical movements	18211
the horizontal displacements	18211
vertical movements	18244
vertical time and vertical activity	18274
vertical time	18274
vertical activity	18292
The responses	18311
the total number of beams	18343
the total number	18343
beams	18363
horizontal and vertical activity	18378
horizontal	18378
vertical activity	18393
time	18419
vertical time	18443
rats	18461
six consecutive 10-minutes periods	18473
CatWalk gait analysis .	18509
CatWalk	18509
gait analysis	18517
CatWalk gait analysis	18532
37 -RSB-	18592
the animals	18606
a horizontal glass runway equipped with a standard CCD camera connected to a computer with the CatWalk software -LRB- Noldus Information Technology , Wageningen , Netherlands -RRB-	18626
a horizontal glass runway	18626
a standard CCD camera connected to a computer with the CatWalk software -LRB- Noldus Information Technology , Wageningen , Netherlands -RRB-	18666
a standard CCD camera	18666
a computer with the CatWalk software -LRB- Noldus Information Technology , Wageningen , Netherlands -RRB-	18701
a computer	18701
the CatWalk software -LRB- Noldus Information Technology , Wageningen , Netherlands -RRB-	18717
the CatWalk software	18717
Noldus Information Technology	18739
Wageningen	18770
Netherlands	18782
Animals	18796
at least three uninterrupted runs per animal	18820
at least three uninterrupted runs	18820
animal	18858
Coordination and different individual paw parameters	18866
functional recovery	18945
Histological studies	18966
All the histological analyses	18988
the correlation between electrophysiological , locomotor and anatomical recovery	19061
the correlation	19061
electrophysiological , locomotor and anatomical recovery	19085
electrophysiological	19085
locomotor	19107
anatomical recovery	19121
we	19142
immunostaining	19155
axonal regrowth , astrocyte reactivity , glial scar and inflammatory response	19174
axonal regrowth	19174
astrocyte reactivity	19191
glial scar	19213
inflammatory response	19228
anaesthetized rats	19260
ice-cold PBS for 2 min and then 4 % paraformaldehyde for 15 min	19319
ice-cold PBS for 2 min	19319
ice-cold PBS	19319
2 min	19336
4 % paraformaldehyde for 15 min	19351
4 % paraformaldehyde	19351
15 min	19375
Spinal cord segments	19383
4 % paraformaldehyde for 24 h	19437
4 % paraformaldehyde	19437
24 h	19461
4 °C	19469
cryopreservation in 30 % sucrose at 4uC	19480
cryopreservation	19480
30 % sucrose at 4uC	19500
30 % sucrose	19500
4uC	19515
spinal cord tissue	19520
longitudinal sections -LRB- 20 µm -RRB- on a cryostat	19552
longitudinal sections -LRB- 20 µm -RRB-	19552
longitudinal sections	19552
20 µm	19575
a cryostat	19585
two rinses in PBS	19607
two rinses	19607
PBS	19621
sections on slides	19626
sections	19626
slides	19638
PBS containing 0.2 % Triton X-100 for 30 min	19670
PBS	19670
0.2 % Triton X-100 for 30 min	19685
0.2 % Triton X-100	19685
30 min	19707
Sections	19715
30 min at room temperature	19739
30 min	19739
room temperature	19749
the corresponding primary antibody : anti-GFAP -LRB- 1/200 , Chemicon , Billerica , MA -RRB- , anti-neurofilament H -LRB- 1/200 , Chemicon -RRB- , anti-Neurocan -LRB- 1 / 200 , Chemicon -RRB- and anti-ED1 -LRB- 1/200 , Chemicon -RRB-	19771
the corresponding primary antibody	19771
anti-GFAP -LRB- 1/200 , Chemicon , Billerica , MA -RRB- , anti-neurofilament H -LRB- 1/200 , Chemicon -RRB- , anti-Neurocan -LRB- 1 / 200 , Chemicon -RRB- and anti-ED1 -LRB- 1/200 , Chemicon -RRB-	19807
anti-GFAP -LRB- 1/200 , Chemicon , Billerica , MA -RRB-	19807
anti-GFAP	19807
1/200	19818
Chemicon	19825
Billerica , MA	19835
anti-neurofilament H -LRB- 1/200 , Chemicon -RRB-	19851
anti-neurofilament H	19851
1/200	19873
Chemicon	19880
anti-Neurocan -LRB- 1 / 200 , Chemicon -RRB-	19891
anti-Neurocan	19891
1	19906
200 , Chemicon	19909
200	19909
Chemicon	19914
anti-ED1 -LRB- 1/200 , Chemicon -RRB-	19928
anti-ED1	19928
1/200	19938
Chemicon	19945
the specificity of the staining	19966
the specificity	19966
the staining	19985
positive and negative controls	19999
the experiments	20054
addition for each experiment , to measure background	20074
addition	20074
each experiment	20087
background	20115
slides without primary antibodies	20127
slides	20127
primary antibodies	20142
primary antibody incubation	20182
sections for ED1 and neurocan stainings	20211
sections	20211
ED1 and neurocan stainings	20224
30 min at room temperature	20266
30 min	20266
room temperature	20276
the PE-conjugated anti-mouse antibody -LRB- 1/500 BD Biosciences -RRB-	20298
the PE-conjugated anti-mouse antibody	20298
1/500 BD Biosciences	20337
1/500	20337
BD Biosciences	20343
GFAP and neurofilament antibodies	20360
Alexa Fluor	20415
488	20428
Images	20433
a fluorescence microscope equipped with apotome -LRB- 1006 ; Axioscope ; Zeiss -RRB-	20472
a fluorescence microscope	20472
apotome -LRB- 1006 ; Axioscope ; Zeiss -RRB-	20512
apotome	20512
1006	20521
Axioscope ; Zeiss	20527
Axioscope	20527
Zeiss	20538
immunodensitometry	20552
areas	20599
1.410	20615
6 pixels -LRB- 2.15 mm2 -RRB- for GFAP , neurofilament , neurocan and ED1 stainings	20621
6 pixels -LRB- 2.15 mm2 -RRB-	20621
6 pixels	20621
2.15 mm2	20631
GFAP , neurofilament , neurocan and ED1 stainings	20645
ImageJ software -LRB- NIH software -RRB-	20699
ImageJ software	20699
NIH software	20716
this	20735
number of positive pixels	20741
number	20741
positive pixels	20751
the measure tool of ImageJ	20785
the measure tool	20785
ImageJ	20805
the threshold defined with control animals -LRB- without surgery -RRB-	20821
the threshold	20821
control animals	20848
surgery	20873
Stamegna et al. -LSB- 19 -RSB-	20898
Stamegna et al. -LSB-	20898
the localization of transplanted OM-OECs into the spinal cord	20931
the localization	20931
transplanted OM-OECs into the spinal cord	20951
transplanted OM-OECs	20951
the spinal cord	20977
GFP-Neurofilament co-staining	20994
anti GFP antibody -LRB- Santa Cruz Biotechnology , CA -RRB-	21044
anti GFP antibody	21044
Santa Cruz Biotechnology	21063
CA	21089
Stainings	21094
MRI	21144
Experiments	21149
7 days	21176
spinal cord transection in 4 other rats for Md , primary OB	21189
spinal cord transection	21189
4 other rats for Md , primary OB	21216
4 other rats	21216
Md , primary OB	21233
Md	21233
primary OB	21237
OM treated groups -LRB- 140 -- 160 g -RRB-	21261
OM treated groups	21261
140 -- 160 g	21280
140	21280
160 g	21284
a 7 Tesla Pharmascan magnet -LRB- Bruker , Germany -RRB- in anesthetized rats -LRB- 1.5 % isoflurane in O2 / N2O 33 % / 67 % -RRB-	21294
a 7 Tesla Pharmascan magnet -LRB- Bruker , Germany -RRB-	21294
a 7 Tesla Pharmascan magnet	21294
Bruker	21323
Germany	21331
anesthetized rats -LRB- 1.5 % isoflurane in O2 / N2O 33 % / 67 % -RRB-	21343
anesthetized rats	21343
1.5 % isoflurane in O2 / N2O 33 % / 67 %	21362
1.5 % isoflurane in O2 / N2O 33 % /	21362
1.5 % isoflurane	21362
O2 / N2O 33 % /	21381
O2	21381
N2O 33 %	21385
67 %	21393
Sagittal T2-weighted images	21399
relaxation enhancement -LRB- RARE -RRB-	21446
relaxation enhancement	21446
RARE	21470
an accelerating factor of 4 -LRB- TR = ≈ 6000 ms , TE = 40 ms , slice thickness = 0.5 mm , planar resolution of 100 µm * 100 µm , acquisition time ≈ 35 minutes -RRB-	21481
an accelerating factor	21481
4 -LRB- TR = ≈ 6000 ms , TE = 40 ms , slice thickness = 0.5 mm , planar resolution of 100 µm * 100 µm , acquisition time ≈ 35 minutes -RRB-	21507
4	21507
TR = ≈ 6000 ms , TE = 40 ms , slice thickness = 0.5 mm , planar resolution of 100 µm * 100 µm , acquisition time ≈ 35 minutes	21510
TR = ≈ 6000 ms	21510
TR =	21510
≈ 6000 ms	21514
TE = 40 ms , slice thickness = 0.5 mm , planar resolution of 100 µm * 100 µm	21524
TE	21524
40 ms , slice thickness	21528
40 ms	21528
slice thickness	21535
0.5 mm , planar resolution of 100 µm * 100 µm	21553
0.5 mm	21553
planar resolution of 100 µm * 100 µm	21561
planar resolution	21561
100 µm	21582
100 µm	21591
acquisition time ≈ 35 minutes	21599
acquisition time	21599
≈ 35 minutes	21616
Image analysis	21630
Image J software	21665
Statistics Prism software -LRB- Graphpad Software , La Jolla , CA . -RRB-	21683
Statistics Prism	21683
software -LRB- Graphpad Software , La Jolla , CA . -RRB-	21700
software	21700
Graphpad Software	21710
La Jolla	21729
CA .	21739
statistics	21757
All data	21769
Catwalk analysis	21790
means	21825
SEM	21833
Nonparametric test	21838
-LRB- Kruskal-Wallis -RRB- , followed by a post test -LRB- Dunns -RRB- ,	21866
-LRB- Kruskal-Wallis -RRB-	21866
a post test -LRB- Dunns -RRB-	21896
a post test	21896
Dunns	21909
differences between the groups	21929
differences	21929
the groups	21949
CatWalk analyses	21965
data	21982
percentage of runs	22004
percentage	22004
runs	22018
a Fisher 's exact test	22046
a Fisher 's	22046
Differences	22083
statistically significant at * p < 0.05 , ** p < 0.01 , or , and *** p < 0.001	22112
statistically significant at * p < 0.05 , ** p < 0.01	22112
statistically significant	22112
p < 0.05 , ** p	22142
p	22142
< 0.05 , ** p	22143
<	22143
0.05 , ** p	22144
0.05	22144
p	22152
< 0.01	22153
<	22153
0.01	22154
*** p < 0.001	22168
*** p <	22168
*** p	22168
0.001	22173
Results Table 1 .	22181
Results	22181
Table 1	22189
Catwalk analysis .	22198
Catwalk	22198
analysis	22206
Figure 1 .	22217
Figure	22217
1	22224
Experimental paradigm illustrating the timeline of the major experimental manipulations .	22227
Experimental paradigm	22227
the timeline of the major experimental manipulations	22262
the timeline	22262
the major experimental manipulations	22278
Cells or medium	22316
sectioned spinal cords -LRB- D0 -RRB-	22355
sectioned spinal cords	22355
D0	22379
15 , 30 and 60 days after surgery animals	22384
15	22384
30 and 60 days after surgery animals	22388
30 and 60 days	22388
surgery animals	22409
electrophysiological and locomotor activities -LRB- D15 , D30 , D60 -RRB-	22443
electrophysiological and locomotor activities	22443
D15 , D30 , D60	22490
Histological analyses	22506
60 days	22543
transplantation for all the groups -LRB- D60 -RRB-	22557
transplantation	22557
all the groups -LRB- D60 -RRB-	22577
all the groups	22577
D60	22593
n = 10	22599
n	22599
= 10	22601
additional animals of OM-purified OECs	22611
additional animals	22611
OM-purified OECs	22633
tracking of GFP + cells	22650
tracking	22650
GFP + cells	22662
GFP	22662
cells	22667
30 and 60	22688
transplantation	22704
D30 , D60	22721
D30	22721
D60	22726
Each time point -LRB- n = 3 -RRB- -LRB- in green -RRB- .	22732
Each time	22732
point -LRB- n = 3 -RRB- -LRB- in green -RRB-	22742
point -LRB- n = 3 -RRB-	22742
point	22742
n	22749
3	22753
Figure 2 .	22769
Figure	22769
2	22776
P75 expression of primary OB -LRB- A -RRB- and OM -LRB- C -RRB- and purified OB-OECs -LRB- B -RRB- and OM-OECs -LRB- D -RRB- cultures .	22779
P75 expression	22779
primary OB -LRB- A -RRB- and OM -LRB- C -RRB- and purified OB-OECs -LRB- B -RRB- and OM-OECs -LRB- D -RRB- cultures	22797
primary OB -LRB- A -RRB- and OM -LRB- C -RRB- and purified OB-OECs -LRB- B -RRB-	22797
primary OB -LRB- A -RRB-	22797
primary OB	22797
A	22809
OM -LRB- C -RRB- and purified OB-OECs -LRB- B -RRB-	22816
OM -LRB- C -RRB-	22816
OM	22816
C	22820
purified OB-OECs -LRB- B -RRB-	22827
purified OB-OECs	22827
B	22845
OM-OECs -LRB- D -RRB- cultures	22852
OM-OECs	22852
D	22861
cultures	22864
5 and 10 days in vitro	22880
5 and 10 days	22880
cell surface expression of p75 in primary OB and purified OB cultures	22904
cell surface expression	22904
p75 in primary OB and purified OB cultures	22931
p75	22931
primary OB and purified OB cultures	22938
primary OB	22938
purified OB cultures	22953
flow cytometry	22992
Primary OB cultures	23008
p75	23046
70 % -LRB- A -RRB-	23053
70 %	23053
A	23058
OB purified cultures	23071
OB	23071
cultures	23083
p75	23110
97 % -LRB- B -RRB-	23117
97 %	23117
B	23122
the same time	23129
5 and 14 days in vitro cell surface expression of p75	23150
5 and 14 days	23150
cell surface expression of p75	23173
cell surface expression	23173
p75	23200
primary OM and purified OM cultures	23222
primary OM	23222
purified OM cultures	23237
flow cytometry	23276
Primary OM cultures	23292
p75	23330
15 % -LRB- C -RRB-	23337
15 %	23337
C	23342
OM purified cultures	23355
OM	23355
cultures	23367
p75	23394
98 % -LRB- D -RRB-	23401
98 %	23401
D	23406
Numbers	23410
the total population and the percentage of cells	23427
the total population	23427
the percentage of cells	23452
the percentage	23452
cells	23470
the indicated gated region	23487
Figure 3 .	23516
Figure	23516
3	23523
Analysis of electrophysiological activities .	23526
Analysis	23526
electrophysiological activities	23538
Measurement of cord dorsum potentials -LRB- A -- C -RRB-	23571
Measurement of cord dorsum potentials	23571
Measurement	23571
cord dorsum potentials	23586
A -- C	23610
A	23610
C	23612
transplantation of OECs	23626
transplantation	23626
OECs	23645
potential amplitude	23668
all OECs treated groups at all-time points studied	23693
all OECs	23693
groups	23710
all-time points studied	23720
all-time points	23720
A -- C	23745
A	23745
C	23747
Md	23751
Medium , OB	23755
Medium	23755
OB	23763
Olfactory Bulb , OM : Olfactory Mucosa	23767
Olfactory Bulb	23767
OM	23783
Olfactory Mucosa	23787
Statistical comparisons	23805
a nonparametric test -LRB- Kruskal-Wallis -RRB-	23850
a nonparametric test	23850
Kruskal-Wallis	23872
Mean6SEM	23889
data	23909
10 rats per group	23919
10 rats	23919
group	23931
p value < 0.05	23941
p value	23941
0.05	23950
Figure 4 .	23957
Figure	23957
4	23964
Analysis of locomotor activities .	23967
Analysis	23967
locomotor activities	23979
A -- C : horizontal activity D -- F : vertical activity and G -- I : vertical time .	24001
A -- C : horizontal activity D -- F	24001
C : horizontal activity D	24003
C	24003
horizontal activity D	24006
vertical activity and G -- I : vertical time	24031
vertical activity and G	24031
vertical activity	24031
G	24053
I : vertical time	24055
I	24055
vertical time	24058
Measurement of locomotor activity -LRB- A -- C -RRB-	24073
Measurement of locomotor activity	24073
Measurement	24073
locomotor activity	24088
A -- C	24108
A	24108
C	24110
there	24126
no significant difference between the groups for horizontal activity at all-time points	24135
no significant difference	24135
the groups for horizontal activity at all-time points	24169
the groups	24169
horizontal activity at all-time points	24184
horizontal activity	24184
all-time points	24207
This analyses	24224
transplantation of Primary OB and Purified OM	24249
transplantation	24249
Primary OB	24268
OM	24292
vertical activity -LRB- F -RRB- and vertical time -LRB- I -RRB- at 60 days	24303
vertical activity	24303
F	24322
vertical time -LRB- I -RRB- at 60 days	24329
vertical time -LRB- I -RRB-	24329
vertical time	24329
I	24344
60 days	24350
Md	24359
Medium , OB	24363
Medium	24363
OB	24371
Olfactory Bulb , OM : Olfactory Mucosa	24375
Olfactory Bulb	24375
OM	24391
Olfactory Mucosa	24395
Statistical comparisons	24413
a nonparametric test -LRB- Kruskal-Wallis -RRB-	24458
a nonparametric test	24458
Kruskal-Wallis	24480
Mean6SEM	24497
data	24517
10 rats per group	24527
10 rats	24527
group	24539
p value < 0.05	24549
p value	24549
0.05	24557
Figure 5 .	24564
Figure	24564
5	24571
Histological analyses	24574
Histological analyses on longitudinal sections	24597
Histological analyses	24597
longitudinal sections	24622
neurofilament -LRB- A -RRB- , GFAP -LRB- G -RRB- , Neurocan -LRB- M -RRB- and ED1 -LRB- T -RRB-	24663
neurofilament -LRB- A -RRB-	24663
neurofilament	24663
A	24678
GFAP -LRB- G -RRB-	24682
GFAP	24682
G	24688
Neurocan -LRB- M -RRB-	24692
Neurocan	24692
M	24702
ED1 -LRB- T -RRB-	24709
ED1	24709
T	24714
These analyses	24718
Primary OB , Purified OB and Purified OM OECs increase axonal regrowth -LRB- neurofilament -RRB- -LRB- A -RRB- ,	24745
Primary OB	24745
OB	24766
OM OECs	24782
axonal regrowth -LRB- neurofilament -RRB- -LRB- A -RRB-	24799
axonal regrowth -LRB- neurofilament -RRB-	24799
axonal regrowth	24799
neurofilament	24816
A	24832
astrocyte reactivity -LRB- GFAP -RRB- -LRB- G -RRB- and glial scar formation -LRB- Neurocan -RRB- -LRB- M -RRB-	24843
astrocyte reactivity -LRB- GFAP -RRB- -LRB- G -RRB-	24843
astrocyte reactivity -LRB- GFAP -RRB-	24843
astrocyte reactivity	24843
GFAP	24865
G	24872
glial scar formation -LRB- Neurocan -RRB- -LRB- M -RRB-	24879
glial scar formation -LRB- Neurocan -RRB-	24879
glial scar formation	24879
Neurocan	24901
M	24912
the same time	24919
this analysis	24933
OECs transplantations	24960
no influence on monocytes/microglia infiltration -LRB- ED1 -RRB- -LRB- T -RRB-	24986
no influence	24986
monocytes/microglia infiltration -LRB- ED1 -RRB- -LRB- T -RRB-	25002
monocytes/microglia infiltration -LRB- ED1 -RRB-	25002
monocytes/microglia infiltration	25002
ED1	25036
T	25042
Typical illustrations	25046
each group for neurofilament -LRB- B -- F -RRB- , GFAP -LRB- H -- L -RRB- , neurocan -LRB- O -- L -RRB- and ED1 -LRB- U -- Y -RRB-	25083
each group	25083
neurofilament -LRB- B -- F -RRB- , GFAP -LRB- H -- L -RRB- , neurocan -LRB- O -- L -RRB- and ED1 -LRB- U -- Y -RRB-	25098
neurofilament -LRB- B -- F -RRB-	25098
neurofilament	25098
B -- F	25113
B	25113
F	25115
GFAP -LRB- H -- L -RRB-	25119
GFAP	25119
H -- L	25125
H	25125
L	25127
neurocan -LRB- O -- L -RRB-	25131
neurocan	25131
O -- L	25141
O	25141
L	25143
ED1 -LRB- U -- Y -RRB-	25150
ED1	25150
U -- Y	25155
U	25155
Y	25157
Md	25161
Medium , OB	25165
Medium	25165
OB	25173
Olfactory Bulb , OM : Olfactory Mucosa	25177
Olfactory Bulb	25177
OM	25193
Olfactory Mucosa	25197
Statistical comparisons	25215
a nonparametric test -LRB- Kruskal - Wallis -RRB-	25260
a nonparametric test	25260
Kruskal - Wallis	25282
Kruskal	25282
Wallis	25291
Mean	25300
SEM	25306
data	25321
10 rats per group	25331
10 rats	25331
group	25343
p value < 0.05 ; ** : p value < 0.01 and *** : p value < 0.001	25353
p value	25353
< 0.05 ; ** : p value < 0.01 and *** : p	25360
<	25360
0.05 ; ** : p value	25361
0.05	25361
p value	25371
< 0.01 and *** : p	25378
<	25378
0.01 and ***	25379
p	25393
< 0.001	25400
<	25400
0.001	25401
Figure 6 .	25409
Figure	25409
6	25416
MRI analyses .	25419
MRI	25419
analyses	25423
MRI analyses	25433
Primary OB -LRB- C -RRB-	25460
Primary OB	25460
C	25472
OM OECs -LRB- D -RRB-	25488
OM OECs	25488
D	25497
inflammatory infiltrate and edema	25510
7 days	25544
transplantation	25557
Boxes	25574
areas of injury	25590
areas	25590
injury	25599
Typical illustrations	25607
control -LRB- A -RRB- , Md -LRB- B -RRB- , Primary OB -LRB- C -RRB-	25643
control -LRB- A -RRB-	25643
control	25643
A	25652
Md -LRB- B -RRB- , Primary OB -LRB- C -RRB-	25656
Md	25656
B	25660
Primary OB -LRB- C -RRB-	25664
Primary OB	25664
C	25676
OM OECs -LRB- D -RRB-	25692
OM OECs	25692
D	25701
Ctrl : Control , Md : Medium , OB : Olfactory Bulb , OM : Olfactory Mucosa .	25705
Ctrl	25705
Control , Md	25711
Control	25711
Md	25720
Medium , OB	25724
Medium	25724
OB	25732
Olfactory Bulb , OM	25736
Olfactory Bulb	25736
OM	25752
Olfactory Mucosa	25756
Olfactory	25756
Mucosa	25766
Illustrations	25774
four different animals for each group	25810
four different animals	25810
each group	25837
Figure 7 .	25850
Figure	25850
7	25857
GFP + OM-OECs	25872
GFP	25872
OM-OECs	25877
GFP + OM-OECs performed on longitudinal sections	25898
GFP + OM-OECs	25898
longitudinal sections	25924
30 -LRB- A -- C -RRB- and 60 -LRB- D -- F -RRB-	25960
30 -LRB- A -- C -RRB-	25960
30	25960
A -- C	25964
A	25964
C	25966
60 -LRB- D -- F -RRB-	25973
60	25973
D -- F	25977
D	25977
F	25979
days after transplantation , OECs could be found at the injury site -LRB- B and E -RRB- and both proximally -LRB- A and D -RRB- and distally	25982
days after transplantation , OECs could be found at the injury site -LRB- B and E -RRB- and both proximally -LRB- A and D -RRB-	25982
days	25982
transplantation	25993
OECs	26010
the injury site -LRB- B and E -RRB- and both proximally -LRB- A and D -RRB-	26033
the injury site	26033
B and E	26050
B	26050
E	26056
both proximally	26063
A and D	26080
A	26080
D	26086
C and F	26103
C	26103
F	26109
the injection site	26115
White arrows	26135
the lesion site	26158
GFP/neurofilament co-staining	26175
OECs	26216
neurofilament + fibers -LRB- G -- I2 -RRB- , 30 and 60 days	26247
neurofilament + fibers -LRB- G -- I2 -RRB-	26247
neurofilament + fibers	26247
G -- I2	26270
G	26270
I2	26272
30 and 60 days	26277
surgery	26298
Scale	26307
100 µm	26319
WH = White Matter and GH = Grey	26327
WH	26327
= White Matter and GH = Grey	26329
Illustrations	26366
three different animals for each time point	26402
three different animals	26402
each time point	26430
Electrophysiological Studies Stimulations	26448
the lesion site	26511
CDP	26531
electrodes placed in gastrocnemius muscles	26555
electrodes	26555
gastrocnemius muscles	26576
These analyses	26599
D15	26629
all OECs treated groups	26634
all OECs	26634
groups	26651
a significant improvement of the CDP amplitudes	26668
a significant improvement	26668
the CDP amplitudes	26697
comparison	26719
the Md group -LRB- p < 0.05 -RRB- -LRB- Figure 3A -RRB-	26733
the Md group -LRB- p < 0.05 -RRB-	26733
the Md group	26733
p < 0.05	26747
p	26747
< 0.05	26748
<	26748
0.05	26749
Figure 3A	26756
Increase of CDP amplitudes	26768
Increase	26768
CDP amplitudes	26780
the full time duration of the experiment	26809
the full time duration	26809
the experiment	26835
all OECs treated groups	26854
all OECs	26854
groups	26871
fact	26882
all OECs treated groups	26888
all OECs	26888
groups	26905
D30 and D60	26922
significantly higher CDP amplitudes	26934
comparison	26973
the Md group -LRB- p < 0.05 -RRB- -LRB- Figures 3B and C -RRB-	26987
the Md group -LRB- p < 0.05 -RRB-	26987
the Md group	26987
p < 0.05	27001
p	27001
< 0.05	27002
<	27002
0.05	27003
Figures 3B and C	27010
this analysis	27033
no difference	27047
the different OECs treated groups -LRB- Figure 3 -RRB-	27087
the different OECs	27087
groups -LRB- Figure 3 -RRB-	27114
groups	27114
Figure 3	27122
These results	27133
transplantations of different types of OECs	27164
transplantations	27164
different types of OECs	27184
different types	27184
OECs	27203
electrophysiological recovery	27223
early -LRB- D15 -RRB- to late time points -LRB- D60 -RRB-	27258
early -LRB- D15 -RRB-	27258
late time points -LRB- D60 -RRB-	27273
late time points	27273
D60	27291
Behavioral Studies Measurement of locomotor activity .	27297
Behavioral Studies	27297
Measurement of locomotor activity	27316
Measurement	27316
locomotor activity	27331
Measurement of horizontal activity	27351
Measurement	27351
horizontal activity	27366
the full duration of the experiment	27407
the full duration	27407
the experiment	27428
all groups	27443
no significant difference	27464
this parameter -LRB- Figures 4A -- C -RRB-	27494
this parameter	27494
Figures 4A -- C	27510
Figures 4A	27510
C	27521
These results	27525
all groups	27556
the same ability to move and to explore	27572
D15 and D30	27616
all the groups	27628
no significant difference	27650
vertical activity and vertical time	27680
vertical activity	27680
vertical time	27702
Figures 4D	27717
Figures	27717
4D	27725
E and G -- H	27728
E and G	27728
H	27736
D60 , Primary OB	27752
OM treated groups presented a significant higher vertical activity -LRB- p < 0.05 -RRB- in comparison to the Md treated group -LRB- Figure 4F -RRB-	27781
OM	27781
treated groups	27784
a significant higher vertical activity -LRB- p < 0.05 -RRB-	27809
a significant higher vertical activity	27809
p < 0.05	27849
p	27849
< 0.05	27850
<	27850
0.05	27851
comparison	27860
the Md treated group -LRB- Figure 4F -RRB-	27874
the Md treated group	27874
Figure 4F	27896
D60 Primary OB	27922
OM treated groups	27950
a significantly higher vertical time -LRB- p < 0.05 -RRB-	27978
a significantly higher vertical time	27978
p < 0.05	28016
p	28016
< 0.05	28017
<	28017
0.05	28018
comparison	28027
the Md treated group -LRB- Figure 4I -RRB-	28041
the Md treated group	28041
Figure 4I	28063
These results	28075
Primary OB	28103
OM	28127
locomotor activity	28142
particular ability to stand up and to maintain a standing position	28165
a standing position	28212
later time -LRB- D60 -RRB-	28236
later time	28236
D60	28248
CatWalk gait analysis .	28254
CatWalk	28254
gait analysis	28262
This analysis	28277
all time points analyzed	28309
all time points	28309
there	28334
no significant differences between all the groups , due to a high intra-group dispersion -LRB- data not shown -RRB-	28344
no significant differences	28344
all the groups , due to a high intra-group dispersion -LRB- data not shown -RRB-	28379
all the groups	28379
a high intra-group dispersion -LRB- data not shown -RRB-	28402
a high intra-group dispersion	28402
data not shown	28433
data	28433
contingency analysis	28459
this	28499
we	28505
all the runs performed by the animals during the three distinct periods -LRB- D15 to D60 -RRB-	28521
all the runs	28521
the animals	28547
the three distinct periods -LRB- D15 to D60 -RRB-	28566
the three distinct periods	28566
D15 to D60	28594
D15	28594
D60	28601
we	28613
the number of successes and failures based on the ability of animals to have walking into the corridor	28629
the number	28629
successes and failures based on the ability of animals to have walking into the corridor	28643
successes and failures	28643
the ability of animals	28675
the ability	28675
animals	28690
the corridor	28719
we	28736
the ratio of successes and failures	28755
the ratio	28755
successes and failures	28768
each group	28795
This analysis	28807
Primary OB , Purified OB and Purified OM treated groups	28833
Primary OB	28833
OB	28854
OM treated groups	28870
a significantly higher rate of runs	28898
a significantly higher rate	28898
runs	28929
comparison	28945
the Md treated animals	28959
0 % of the Md treated group	28991
0 %	28991
the Md treated group	28997
all the runs	29042
comparison , 21.6 % of the Primary OB -LRB- p < 0.05 -RRB- , 26 % of the Purified OB -LRB- 0.01 < p < 0.001 -RRB- and 36.7 % of the Purified OM treated animals -LRB- p < 0.001 -RRB- were able to walk into the corridor during all the runs -LRB- Table 1 -RRB-	29059
comparison	29059
21.6 % of the Primary OB -LRB- p < 0.05 -RRB- , 26 % of the Purified OB -LRB- 0.01 < p < 0.001 -RRB- and 36.7 % of the Purified OM treated animals -LRB- p < 0.001 -RRB- were able to walk into the corridor during all the runs -LRB- Table 1 -RRB-	29071
21.6 %	29071
the Primary OB -LRB- p < 0.05 -RRB- , 26 % of the Purified OB -LRB- 0.01 < p < 0.001 -RRB- and 36.7 % of the Purified OM treated animals -LRB- p < 0.001 -RRB- were able to walk into the corridor during all the runs -LRB- Table 1 -RRB-	29080
the Primary OB -LRB- p < 0.05 -RRB-	29080
the Primary OB	29080
p < 0.05	29096
p	29096
< 0.05	29097
<	29097
0.05	29098
26 % of the Purified OB -LRB- 0.01 < p < 0.001 -RRB- and 36.7 % of the Purified OM treated animals -LRB- p < 0.001 -RRB- were able to walk into the corridor during all the runs -LRB- Table 1 -RRB-	29105
26 %	29105
the Purified OB -LRB- 0.01 < p < 0.001 -RRB- and 36.7 % of the Purified OM treated animals -LRB- p < 0.001 -RRB- were able to walk into the corridor during all the runs -LRB- Table 1 -RRB-	29112
the Purified OB -LRB- 0.01 < p < 0.001 -RRB-	29112
the Purified OB	29112
0.01 < p < 0.001	29129
0.01 < p	29129
< 0.001	29135
<	29135
0.001	29136
36.7 % of the Purified OM treated animals -LRB- p < 0.001 -RRB- were able to walk into the corridor during all the runs -LRB- Table 1 -RRB-	29147
36.7 %	29147
the Purified OM treated animals -LRB- p < 0.001 -RRB- were able to walk into the corridor during all the runs -LRB- Table 1 -RRB-	29156
the Purified OM	29156
animals -LRB- p < 0.001 -RRB-	29180
animals	29180
p < 0.001	29189
p	29189
< 0.001	29190
<	29190
0.001	29191
the corridor	29221
all the runs -LRB- Table 1 -RRB-	29241
all the runs	29241
Table 1	29255
OM treated group	29284
OM	29284
group	29295
a significantly higher probability	29308
comparison	29354
the Primary OM treated animals -LRB- p < 0.05 -RRB-	29368
the Primary OM	29368
animals -LRB- p < 0.05 -RRB-	29391
animals	29391
p < 0.05	29400
p	29400
< 0.05	29401
<	29401
0.05	29402
These results	29408
Primary OB , Purified OB and Purified OM treated groups , but not Primary OM treated group	29439
Primary OB	29439
OB	29460
OM treated groups , but not Primary OM treated group	29476
OM treated groups	29476
OM	29476
treated groups	29479
Primary OM treated group	29503
Primary OM	29503
group	29522
ability	29540
Histological Analysis All the histological analyses	29557
Histological Analysis	29557
All the histological analyses	29579
longitudinal sections	29627
D60	29653
histological analyses on an equivalent area	29658
histological analyses	29658
an equivalent area	29683
Primary OB , Purified OB and Purified OM treated groups presented a significantly higher staining for neurofilament ,	29716
Primary OB	29716
OB	29737
OM treated groups presented a significantly higher staining for neurofilament	29753
OM	29753
treated groups	29756
a significantly higher staining for neurofilament	29781
a significantly higher staining	29781
neurofilament	29817
a marker of axonal regrowth , in comparison	29840
a marker	29840
axonal regrowth	29852
comparison	29872
Md treated group -LRB- p < 0.05 -RRB- -LRB- Figure 5A -RRB-	29886
Md treated group -LRB- p < 0.05 -RRB-	29886
Md treated group	29886
p < 0.05	29904
p	29904
< 0.05	29905
<	29905
0.05	29906
Figure 5A	29913
Primary OM treated group	29925
Primary OM	29925
group	29944
difference	29963
Md treated group -LRB- Figure 5A -RRB-	29979
Md treated group	29979
Figure 5A	29997
Representative pictures	30009
each group for neurofilament staining -LRB- Figures 5B -- F -RRB-	30051
each group	30051
neurofilament staining -LRB- Figures 5B -- F -RRB-	30066
neurofilament staining	30066
Figures 5B -- F	30090
Figures 5B	30090
F	30101
similar histological analyses	30117
all OECs treated groups	30161
all OECs	30161
groups	30178
a significantly lower staining for GFAP , used as a marker of astrocyte reactivity ,	30195
a significantly lower staining	30195
GFAP	30230
a marker of astrocyte reactivity	30244
a marker	30244
astrocyte reactivity	30256
comparison	30281
Md treated group -LRB- p < 0.05 -RRB- -LRB- Figure 5G -RRB-	30295
Md treated group -LRB- p < 0.05 -RRB-	30295
Md treated group	30295
p < 0.05	30313
p	30313
< 0.05	30314
<	30314
0.05	30315
Figure 5G	30322
38 -RSB-	30334
Representative pictures	30339
each group for GFAP staining -LRB- Figures 5H -- L -RRB-	30381
each group	30381
GFAP staining -LRB- Figures 5H -- L -RRB-	30396
GFAP staining	30396
Figures 5H -- L	30411
Figures 5H	30411
L	30422
We	30426
neurocan staining , an extracellular matrix -LRB- ECM -RRB- protein	30444
neurocan staining	30444
an extracellular matrix -LRB- ECM -RRB- protein	30463
an extracellular matrix	30463
ECM	30488
protein	30493
the glial scar	30512
all OECs treated groups	30544
all OECs	30544
groups	30561
a significant reduction for this staining -LRB- 0.01 < p < 0.001 for Primary OM and OB treated groups and p < 0.001 for Purified OB and OM treated groups -RRB-	30578
a significant reduction	30578
this staining -LRB- 0.01 < p < 0.001 for Primary OM and OB treated groups and p < 0.001 for Purified OB and OM treated groups -RRB-	30606
this staining	30606
0.01 < p <	30621
0.01 < p	30621
0.001 for Primary OM and OB treated groups and p	30628
0.001	30628
Primary OM and OB treated groups and p	30638
Primary OM	30638
OB treated groups and p	30653
OB treated groups	30653
p	30675
0.001	30677
OB and OM treated groups	30696
OB	30696
OM treated groups	30703
comparison	30725
Md treated group -LRB- Figure 5M -RRB-	30739
Md treated group	30739
Figure 5M	30757
interest	30772
OM treated group	30791
OM	30791
group	30802
the greatest reduction of neurocan staining -LRB- p < 0.05 -RRB-	30815
the greatest reduction	30815
neurocan staining -LRB- p < 0.05 -RRB-	30841
neurocan staining	30841
p < 0.05	30860
p	30860
< 0.05	30861
<	30861
0.05	30862
Representative pictures	30869
each group for neurocan staining -LRB- Figures 5O -- S -RRB-	30911
each group	30911
neurocan staining -LRB- Figures 5O -- S -RRB-	30926
neurocan staining	30926
Figures 5O -- S	30945
Figures 5O	30945
S	30956
D60	30963
there	30968
no difference in ED1 staining , used as a marker of activated microglia , monocytes and macrophages , between all groups	30978
no difference	30978
ED1 staining	30995
a marker of activated microglia , monocytes and macrophages	31017
a marker	31017
activated microglia , monocytes and macrophages	31029
all groups	31085
fact	31100
all groups	31106
a high ED1	31127
invasion	31139
the spinal cord parenchyma -LRB- Figure 5T -RRB-	31153
the spinal cord parenchyma	31153
Figure 5T	31181
Representative pictures	31193
each group for ED1 staining -LRB- Figures 5U -- Y -RRB-	31235
each group	31235
ED1 staining -LRB- Figures 5U -- Y -RRB-	31250
ED1 staining	31250
Figures 5U -- Y	31264
Figures 5U	31264
Y	31275
Complementary analyses	31278
order	31319
the potential presence of distinct subpopulations of macrophages -LRB- M1 and M2 -RRB-	31338
the potential presence	31338
distinct subpopulations of macrophages -LRB- M1 and M2 -RRB-	31364
distinct subpopulations	31364
macrophages -LRB- M1 and M2 -RRB-	31391
macrophages	31391
M1 and M2	31404
M1	31404
M2	31411
the ED1 + cells	31420
the ED1	31420
cells	31429
this	31440
histological analyses based on MMP9-ED1 co-staining	31446
histological analyses	31446
MMP9-ED1 co-staining	31477
no difference	31513
the groups -LRB- data not shown -RRB-	31553
the groups	31553
data not shown	31565
data	31565
We	31582
these results	31603
an in vitro approach using macrophages -LRB- NR8383 cells -RRB- cultured with conditioned medium obtained from OM and OB-OECs -LSB- 7 -RSB-	31620
an in vitro approach	31620
macrophages -LRB- NR8383 cells -RRB-	31647
macrophages	31647
NR8383 cells	31660
conditioned medium obtained from OM	31688
conditioned medium	31688
OM	31721
-LSB- 7 -RSB-	31736
Quantification of IL-12 and IL-10 secretion	31741
Quantification	31741
IL-12 and IL-10 secretion	31759
conditioned medium from OM or OB-OECs	31797
conditioned medium	31797
OM or OB-OECs	31821
no effect on macrophage phenotype in culture -LRB- data not shown -RRB-	31839
no effect	31839
macrophage phenotype in culture -LRB- data not shown -RRB-	31852
macrophage phenotype	31852
culture	31876
data not shown	31885
data	31885
these results	31914
all OECs treated groups presented a reduction of GFAP -LRB- astrocyte reactivity -RRB- and neurocan -LRB- glial scar component -RRB- stainings in comparison to Md treated group and in particular Purified OM treated group	31945
all OECs	31945
groups	31962
a reduction of GFAP -LRB- astrocyte reactivity -RRB- and neurocan -LRB- glial scar component -RRB- stainings in comparison	31979
a reduction of GFAP -LRB- astrocyte reactivity -RRB-	31979
a reduction	31979
GFAP	31994
astrocyte reactivity	32000
neurocan -LRB- glial scar component -RRB-	32026
neurocan	32026
glial scar component	32036
stainings in comparison	32058
stainings	32058
comparison	32071
Md treated group	32085
particular Purified OM treated group	32109
particular	32109
OM treated group	32129
OM	32129
group	32140
a significantly greater reduction of neurocan expression in comparison	32156
a significantly greater reduction	32156
neurocan expression in comparison	32193
neurocan expression	32193
comparison	32216
all the other OECs treated groups	32230
all the other OECs	32230
groups	32257
it	32273
Primary OB , Purified OB and Purified OM treated groups and not Primary OM treated group	32303
Primary OB , Purified OB and Purified OM treated groups	32303
Primary OB	32303
OB	32324
OM treated groups	32340
Primary OM treated group	32366
Primary OM	32366
group	32385
an increase of the axonal regrowth -LRB- neurofilament -RRB-	32398
an increase	32398
the axonal regrowth -LRB- neurofilament -RRB-	32413
the axonal regrowth	32413
neurofilament	32434
comparison	32452
Md treated group	32466
MRI Analysis	32484
the inflammatory infiltrate and formation of the glial scar	32516
the inflammatory infiltrate and formation	32516
the glial scar	32561
early time point	32579
surgery and/or cellular transplantation	32602
surgery	32602
cellular transplantation	32617
we	32643
MRI experiments	32656
7 days	32678
this analysis 4 other rats of Md , Primary OB and Purified OM	32690
this analysis 4 other rats of Md	32690
this analysis	32690
4 other rats of Md	32704
4 other rats	32704
Md	32720
Primary OB	32724
OM	32748
treated groups , which showed higher potential to promote recovery ,	32751
treated groups	32751
higher potential to promote recovery	32780
higher potential	32780
recovery	32808
animals -LRB- Figures 6C and D -RRB-	32842
animals	32842
Figures 6C and D	32851
a reduction of the signal intensity -LRB- delimited by white areas -RRB-	32879
a reduction	32879
the signal intensity	32894
white areas	32929
comparison	32945
the hyperintense sequences of the Md	32959
the hyperintense sequences	32959
the Md	32989
treated animals -LRB- Figure 6B -RRB-	32996
treated animals	32996
Figure 6B	33013
This result based on T2 * IRM sequences	33025
This result	33025
T2 * IRM sequences	33046
T2	33046
IRM sequences	33050
OEC transplantations	33079
inflammatory infiltrate and edema	33107
the spinal cord parenchyma at early time	33146
the spinal cord parenchyma	33146
early time	33176
Animals without surgery	33188
Animals	33188
surgery	33204
control -LRB- Figure 6A -RRB-	33222
control	33222
Figure 6A	33231
GFP + OM-OECs	33255
GFP	33255
OM-OECs	33260
this analysis	33272
6 other rats for Purified OM treated group , which constituted the most relevant group for clinical use ,	33287
6 other rats	33287
OM treated group	33313
OM	33313
group	33324
the most relevant group for clinical use	33349
the most relevant group	33349
clinical use	33377
GFP + OM-OECs	33414
GFP	33414
OM-OECs	33419
30 and 60 days after surgery	33441
30 and 60 days	33441
surgery	33462
3 rats for each time point	33473
3 rats	33473
each time point	33484
Histological analyses , based on longitudinal sections ,	33501
Histological analyses	33501
longitudinal sections	33533
a similarly high number of GFP + cells	33570
a similarly high number	33570
GFP + cells	33597
GFP	33597
cells	33602
the lesion site and both distally -LRB- Figures 7C and F -RRB-	33626
the lesion site and both distally	33626
the lesion site and both	33626
the lesion site	33626
both	33646
Figures 7C and F	33661
Figures 7A and D	33695
the injection site	33716
both time points in all the rats transplanted	33738
both time points	33738
all the rats transplanted	33758
all the rats	33758
Image analysis	33785
OECs	33818
a distance of 1.5 cm	33838
a distance	33838
1.5 cm	33852
a maximal distance of the injection sites of around 0.35 cm	33866
a maximal distance	33866
the injection sites of around 0.35 cm	33888
the injection sites	33888
0.35 cm	33918
It	33927
the lesion site	33951
gap	33980
60 days	33984
transplantation -LRB- white arrows -RRB- -LRB- Figure 7E -RRB- in contrary to 30 days after transplantation	33998
transplantation -LRB- white arrows -RRB-	33998
transplantation	33998
white arrows	34015
Figure 7E	34030
contrary to 30 days after transplantation	34044
contrary to 30 days	34044
30	34056
transplantation	34070
Figure 7B	34087
the localization of OECs	34110
the localization	34110
OECs	34130
the spinal cord	34140
GFPNeurofilament co-staining	34157
OECs	34215
neurofilament	34247
30 and 60 days after surgery -LRB- Figures 7G -- I2 -RRB-	34261
30 and 60 days	34261
surgery -LRB- Figures 7G -- I2 -RRB-	34282
surgery	34282
Figures 7G -- I2	34291
Figures 7G	34291
I2	34302
these results	34319
OM-OECs	34350
60 days	34376
axons	34427
the lesioned spinal cord	34436
Discussion Numerous reports	34462
the role of OECs transplantations	34516
the role	34516
OECs transplantations	34528
SCI using different experimental paradigms -LSB- 13,38 -- 42 -RSB-	34556
SCI	34556
different experimental paradigms -LSB- 13,38 -- 42 -RSB-	34566
different experimental paradigms -LSB- 13,38	34566
different experimental paradigms	34566
13,38	34600
42 -RSB-	34606
none of these studies	34620
none	34620
these studies	34628
the therapeutic benefit of OM and OB-OECs	34664
the therapeutic benefit	34664
OM and OB-OECs	34691
primary	34712
cultures	34732
electrophysiological , functional and histological analyses	34745
our knowledge	34808
this	34823
the first report which described by a multi-parametric approach the effects of OECs from different sources in a severe SCI model	34831
the first report	34831
a multi-parametric approach	34867
the effects of OECs from different sources in a severe SCI model	34895
the effects	34895
OECs from different sources in a severe SCI model	34910
OECs	34910
different sources in a severe SCI model	34920
different sources	34920
a severe SCI model	34941
our study	34965
we	34975
a complete transection model	34990
the fact	35026
this model	35040
a permanent disability	35086
lesioned animals -LSB- 43,44 -RSB-	35112
lesioned animals	35112
43,44 -RSB-	35130
the completeness and the reproducibility of the section	35151
the completeness	35151
the reproducibility of the section	35172
the reproducibility	35172
the section	35195
all the surgeries	35207
the same operator -LRB- A.M -RRB-	35248
the same operator	35248
A.M	35267
preliminary animals	35276
we	35320
immediate electrophysiology analyses	35338
transection	35381
the abolition of the electrical signal	35411
the abolition	35411
the electrical signal	35428
Locomotor activity and catwalk tests	35451
BBB	35523
functional recovery	35538
they	35567
computer-assisted analysis	35576
quantitative data	35624
a great precision	35647
lomomotor activity analyses	35674
all the lesioned animals	35716
the same horizontal activity -LRB- ability to move -RRB-	35746
the same horizontal activity	35746
ability to move	35776
ability	35776
OECs transplantations	35802
ability in Primary OB	35853
ability	35853
Primary OB	35864
OM treated animals	35888
OM	35888
animals	35899
These results	35908
Md animals	35933
Figure	35984
Our results	35995
transplantation of OECs	36024
transplantation	36024
OECs	36043
a very promising therapy for SCI independently of their source	36060
a very promising therapy	36060
SCI independently of their source	36089
SCI	36089
their source	36110
OECs	36132
electrophysiological and functional recovery -LRB- Figures 3 and 4 and Table	36145
electrophysiological	36145
functional recovery -LRB- Figures 3 and 4 and Table	36170
functional recovery	36170
Figures 3 and 4 and Table	36191
Figures 3 and 4	36191
Table	36211
1 -RRB- , reduced astrocyte reactivity and glial scar -LRB- based on neurocan expression -RRB- and improved axonal regrowth -LRB- Figure 5 -RRB-	36217
1 -RRB- , reduced astrocyte reactivity and glial scar -LRB- based on neurocan expression -RRB-	36217
astrocyte reactivity	36229
glial	36254
scar -LRB- based on neurocan expression -RRB-	36260
scar	36260
neurocan expression	36275
improved axonal regrowth -LRB- Figure 5 -RRB-	36300
improved axonal regrowth	36300
Figure 5	36326
ED1 staining	36352
OECs	36379
no effect on macrophage / microglia response 60 days after SCI -LRB- Figure 5 -RRB-	36397
no effect	36397
macrophage / microglia response 60 days after SCI -LRB- Figure 5 -RRB-	36410
macrophage / microglia response 60 days after SCI	36410
macrophage	36410
microglia response 60 days	36422
microglia response	36422
60 days	36441
SCI	36455
Figure 5	36460
ability of OECs to modulate processes and formation of the glial scar at early time point after surgery and/or cellular transplantation	36490
ability	36490
OECs to modulate processes and formation of the glial scar at early time point after surgery and/or cellular transplantation	36501
processes and formation of the glial scar	36518
processes and formation	36518
the glial scar	36545
early time point	36563
surgery and/or cellular transplantation	36586
surgery	36586
cellular transplantation	36601
MRI analyses	36626
Seven days	36655
surgery	36672
the MRI sequences in treated groups	36680
the MRI sequences	36680
treated groups	36701
a reduction of the signal intensity	36723
a reduction	36723
the signal intensity	36738
comparison	36762
the untreated group	36776
These results	36797
a reduction of the inflammatory infiltrate and edema	36835
a reduction	36835
the inflammatory infiltrate and edema	36850
a reduction of the cystic cavities	36894
a reduction	36894
the cystic cavities	36909
Both of these hypotheses	36930
Both	36930
these hypotheses	36938
a decrease of the inflammatory processes	36972
a decrease	36972
the inflammatory processes	36986
7 days	37013
surgery in transplanted groups -LRB- Primary OB and Purified OM groups -RRB-	37026
surgery	37026
transplanted groups -LRB- Primary OB and Purified OM groups -RRB-	37037
transplanted groups	37037
Primary OB and Purified OM groups	37058
Primary OB	37058
OM groups	37082
Our results	37094
electric recovery -LRB- based on measurement of cord dorsum potentials -RRB-	37124
electric recovery	37124
measurement of cord dorsum potentials	37152
measurement	37152
cord dorsum potentials	37167
transplantation -LRB- D15 -RRB-	37212
transplantation	37212
D15	37229
treated groups	37237
this recovery	37262
later functional recovery in primary OB	37291
later functional recovery	37291
primary OB	37320
OM-OECs	37344
treated groups -LRB- D60 -RRB-	37352
treated groups	37352
D60	37368
These results	37374
the fact that to induce functional recovery	37419
the fact	37419
functional recovery	37443
neurons	37464
regrowth	37489
connections	37515
neuronal network	37541
no significant difference about functional recovery	37568
no significant difference	37568
functional recovery	37600
OB-Primary and OM-Purified groups	37642
our study	37677
OECs	37703
OM present the best benefit/risk ratio	37735
OM present	37735
the best benefit/risk ratio	37746
This result	37775
a fundamental point	37790
a future human clinical application	37814
the fact	37858
OM	37872
the more accessible source for OECs	37878
the more accessible source	37878
OECs	37909
our study	37918
purification of primary cultures	37953
purification	37953
primary cultures	37969
no effect in case of transplantation of OECs obtained from OB -LRB- Figures 3 -- 5 and Table	37990
no effect	37990
case of transplantation of OECs obtained from OB -LRB- Figures 3 -- 5 and Table	38003
case	38003
transplantation of OECs obtained from OB -LRB- Figures 3 -- 5 and Table	38011
transplantation	38011
OECs obtained from OB -LRB- Figures 3 -- 5 and Table	38030
OECs	38030
OB -LRB- Figures 3 -- 5 and Table	38049
OB -LRB- Figures 3	38049
OB	38049
Figures 3	38053
Figures	38053
3	38061
5 and Table	38063
5	38063
Table	38069
which	38078
several ways -LSB- 24 -RSB-	38104
several ways	38104
24 -RSB-	38118
deprivation of microenvironment	38130
deprivation	38130
microenvironment	38145
a loss of the two distinct subpopulations of OECs	38170
a loss	38170
the two distinct subpopulations of OECs	38180
the two distinct subpopulations	38180
OECs	38215
primary OB cultures	38231
a decrease in the recovery of the treated animals -LSB- 21 -RSB-	38263
a decrease	38263
the recovery of the treated animals -LSB- 21 -RSB-	38277
the recovery	38277
the treated animals -LSB- 21 -RSB-	38293
the treated animals	38293
21 -RSB-	38314
the rate of OECs	38328
the rate	38328
OECs	38340
70 % in primary OB cultures which might not be a limiting factor for functional and anatomical recovery in our SCI model	38355
70 %	38355
primary OB cultures	38362
a limiting factor for functional and anatomical recovery in our SCI model	38401
a limiting factor	38401
functional and anatomical recovery in our SCI model	38423
functional and anatomical recovery	38423
our SCI model	38461
the `` fibroblast-like '' cells present in primary OB cultures	38485
the `` fibroblast-like '' cells	38485
primary OB cultures	38526
an important role	38555
the integration of OECs in the spinal cord -LSB- 28,45 -RSB-	38577
the integration	38577
OECs in the spinal cord -LSB- 28,45 -RSB-	38596
OECs	38596
the spinal cord -LSB- 28,45 -RSB-	38604
the spinal cord	38604
28,45 -RSB-	38621
a recent study	38637
the main role of fibroblasts on SC	38667
the main role	38667
fibroblasts on SC	38684
fibroblasts	38684
SC	38699
axonal regrowth	38706
Wallerian degeneration in peripheral nerve injury -LRB- PNI -RRB- -LSB- 46 -RSB-	38728
Wallerian degeneration	38728
peripheral nerve injury -LRB- PNI -RRB- -LSB- 46 -RSB-	38754
peripheral nerve injury -LRB- PNI -RRB-	38754
peripheral nerve injury	38754
PNI	38779
46 -RSB-	38785
It	38790
the common origin of SC and OECs	38831
the common origin	38831
SC and OECs	38852
`` fibroblast-like '' cells have the same influence on OECs , even in the case of transplantation in a lesioned spinal cord	38870
`` fibroblast-like '' cells	38870
the same influence	38901
OECs	38923
the case of transplantation	38937
the case	38937
transplantation	38949
a lesioned spinal cord	38968
14,47 -RSB-	38992
contrast	39003
purification of OECs from OM cultures	39013
purification	39013
OECs from OM cultures	39029
OECs	39029
OM cultures	39039
both functional and anatomical recoveries which is highly relevant for future clinical applications	39074
both functional and anatomical recoveries	39074
future clinical applications	39145
Several hypotheses	39175
the differences observed between primary and purified cultures upon transplantation	39208
the differences	39208
primary	39241
cultures	39262
transplantation	39276
primary OM cultures	39300
a relatively low content of OECs -LRB- 15 % -RRB- which could explain the poor functional recovery of this group	39325
a relatively low content	39325
OECs -LRB- 15 % -RRB- which could explain the poor functional recovery of this group	39353
OECs	39353
15 %	39359
the poor functional recovery of this group	39384
the poor functional recovery	39384
this group	39416
several studies	39442
benefic functional effects	39472
transplantation of low dose of OECs -LSB- 16,48 -RSB-	39505
transplantation	39505
low dose of OECs -LSB- 16,48 -RSB-	39524
low dose	39524
OECs -LSB- 16,48 -RSB-	39536
OECs	39536
16,48 -RSB-	39542
Another hypothesis	39550
cells	39591
primary OM cultures	39608
axonal regrowth	39636
our study	39656
histological analyses	39667
Primary OM	39703
group displayed no difference according to neurofilament staining in comparison	39722
group	39722
no difference	39738
neurofilament staining in comparison	39765
neurofilament staining	39765
comparison	39791
Md group	39805
the same time Purified OM treated	39826
the same time	39826
OM treated	39849
OM	39849
group	39860
a significant increase	39873
this parameter -LRB- p ,0.05 -RRB- -LRB- Figure 5 -RRB-	39900
this parameter -LRB- p ,0.05 -RRB-	39900
this parameter	39900
p ,0.05	39916
Figure 5	39925
We	39936
transplantation of primary OM cultures after PNI	39969
transplantation	39969
primary OM cultures after PNI	39988
primary OM cultures	39988
PNI	40014
functional recovery	40026
improvement of axonal regrowth -LSB- 23 -RSB-	40054
improvement	40054
axonal regrowth -LSB- 23 -RSB-	40069
axonal regrowth	40069
23 -RSB-	40086
The microenvironment present in primary OM cultures	40091
The microenvironment	40091
primary OM cultures	40123
a higher mortality	40161
cellular transplantation	40186
One last hypothesis	40212
the purification method used	40240
the purification method	40240
privative medium	40279
modification or selection of specific cell subpopulations	40310
modification or selection	40310
specific cell subpopulations	40339
A recent study	40369
primary OM cultures	40402
distinct populations of cells	40430
distinct populations	40430
cells	40454
OECs , therefore serum deprivation may select specifically one of them -LSB-	40475
OECs	40475
serum deprivation may select specifically one of them	40491
serum deprivation	40491
one of them	40533
one	40533
them	40540
49 -RSB-	40546
Complementary studies	40551
this specific point	40604
Previous studies	40625
OM and OB-OECs	40656
cultures	40688
PNI	40707
vivo -LSB- 23,50,51 -RSB-	40714
vivo	40714
23,50,51 -RSB-	40720
They	40731
some differences such as distinct ability	40747
some differences	40747
distinct ability	40772
axonal regrowth	40799
ECM	40828
primary olfactory neurons -LSB- 23,50,51 -RSB-	40853
primary olfactory neurons	40853
23,50,51 -RSB-	40880
our present study	40894
no major differences in functional recovery after transplantation of OM and OB-OECs	40913
no major differences	40913
functional recovery after transplantation of OM and OB-OECs	40937
functional recovery	40937
transplantation of OM and OB-OECs	40963
transplantation	40963
OM and OB-OECs	40982
SCI -LRB- Figures 3 -- 5 -RRB-	41016
SCI	41016
Figures 3 -- 5	41021
Figures 3	41021
5	41031
our histological analyses	41044
a significant difference between these groups	41079
a significant difference	41079
these groups	41112
fact	41129
neurocan staining	41135
OM group	41174
a significant reduction of this parameter in comparison	41193
a significant reduction	41193
this parameter in comparison	41220
this parameter	41220
comparison	41238
Primary OB	41252
OB treated groups -LRB- p ,0.05 -RRB- -LRB- Figure 5 -RRB-	41276
OB treated groups -LRB- p ,0.05 -RRB-	41276
OB treated groups	41276
p ,0.05	41295
Figure 5	41304
it	41325
ADAMTS-4	41348
a major role	41368
degradation of the glial scar	41384
degradation	41384
the glial scar	41399
chondroitin sulfate proteoglycans -LRB- CSPG -RRB-	41423
chondroitin sulfate proteoglycans	41423
CSPG	41458
a major component of the glial scar with axonal growth inhibitory properties	41468
a major component	41468
the glial scar with axonal growth inhibitory properties	41489
the glial scar	41489
axonal growth inhibitory properties	41509
it	41556
ADAMTS-4	41574
CSPG as neurocan , brevican and phosphacan	41597
CSPG	41597
neurocan , brevican and phosphacan	41605
vivo	41655
local administration of ADAMTS-4	41669
local administration	41669
ADAMTS-4	41693
functional recovery	41714
SCI	41740
4 -RSB-	41745
We	41749
ADAMTS-4	41779
OM-OECs	41816
OB-OECs in vitro -LSB- 20 -RSB-	41832
OB-OECs	41832
-LSB- 20 -RSB-	41849
We	41855
this result	41881
the protein level -LRB- data not shown -RRB-	41896
the protein level	41896
data not shown	41915
data	41915
Previous studies	41932
the ability of OM-OECs	41967
the ability	41967
OM-OECs	41982
the ECM -LSB- 35,52 -RSB-	42002
the ECM	42002
35,52 -RSB-	42011
complementary studies on the capacity of OM-OECs , in particular the potential role of ADAMTS-4 to regulate glial scar ,	42030
complementary studies	42030
the capacity of OM-OECs	42055
the capacity	42055
OM-OECs	42071
particular the potential role of ADAMTS-4 to regulate glial scar	42083
particular the potential role	42083
ADAMTS-4	42116
glial scar	42137
Visualization of GFP	42170
Visualization	42170
GFP	42187
OM-OECs	42199
they	42219
neurofilament + fibers -LRB- Figure 6 -RRB-	42263
neurofilament + fibers	42263
Figure 6	42286
We	42297
OM-OECs	42312
the injured spinal cord	42339
up to 60 days	42379
OM-OECs , in our model ,	42394
OM-OECs	42394
our model	42406
3.5 mm , a distance close to previously reported genetically modified SC -LRB- 4.4 mm -RRB- -LSB- 8 -RSB-	42432
3.5 mm	42432
a distance close to previously reported genetically modified SC -LRB- 4.4 mm -RRB- -LSB- 8 -RSB-	42440
a distance close	42440
genetically modified SC -LRB- 4.4 mm -RRB-	42480
genetically modified SC	42480
4.4 mm	42505
8 -RSB-	42514
These results	42518
the potential of OM-OECs	42542
the potential	42542
OM-OECs	42559
the injured spinal cord	42600
the accessibility and the recovery properties of OECs	42637
the accessibility	42637
the recovery properties of OECs	42659
the recovery properties	42659
OECs	42686
them	42708
a future relevant biotherapy for spinal cord repair	42716
a future relevant biotherapy	42716
spinal cord repair	42749
Several types of cellular transplantations	42769
Several types	42769
cellular transplantations	42786
SCI recovery	42840
rodent models	42856
few of these	42879
few	42879
these	42886
clinical use	42914
fact for a human application	42931
fact	42931
a human application	42940
the cells	42961
adult	43017
weak risk of teratogenicity	43037
weak risk	43037
teratogenicity	43050
functional recovery	43081
OECs	43102
all these advantages and criteria	43112
OM-OECs	43161
nasal biopsies	43190
high purity	43223
a high benefit / risk balance due to the fact that OECs are differentiated cells , are stable even after long term cultures from adult primates and induce functional and anatomical recoveries -LSB- 29,34 -RSB-	43247
a high benefit	43247
risk balance due to the fact that OECs are differentiated cells , are stable even after long term cultures from adult primates and induce functional and anatomical recoveries -LSB- 29,34	43263
risk balance due to the fact that OECs are differentiated cells , are stable even after long term cultures from adult primates and induce functional	43263
risk balance	43263
the fact that OECs are differentiated cells , are stable even after long term cultures from adult primates and induce functional	43283
the fact	43283
OECs	43297
cells	43321
long term cultures	43350
adult primates	43374
anatomical recoveries -LSB- 29,34	43415
anatomical recoveries	43415
29,34	43438
We	43446
the potential of different OECs sources	43467
the potential	43467
different OECs sources	43484
a better molecular understanding on the culture effect and subpopulations	43516
a better molecular understanding	43516
the culture effect and subpopulations	43552
the culture effect	43552
subpopulations	43575
the clinical potential and use of OECs for SCI	43614
the clinical potential and use	43614
OECs for SCI	43648
OECs	43648
SCI	43657
